<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35740354</PMID><DateRevised><Year>2022</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2227-9059</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>6</Issue><PubDate><Year>2022</Year><Month>Jun</Month><Day>06</Day></PubDate></JournalIssue><Title>Biomedicines</Title><ISOAbbreviation>Biomedicines</ISOAbbreviation></Journal><ArticleTitle>Unbalanced IDO1/IDO2 Endothelial Expression and Skewed Keynurenine Pathway in the Pathogenesis of COVID-19 and Post-COVID-19 Pneumonia.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1332</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/biomedicines10061332</ELocationID><Abstract><AbstractText>Despite intense investigation, the pathogenesis of COVID-19 and the newly defined long COVID-19 syndrome are not fully understood. Increasing evidence has been provided of metabolic alterations characterizing this group of disorders, with particular relevance of an activated tryptophan/kynurenine pathway as described in this review. Recent histological studies have documented that, in COVID-19 patients, indoleamine 2,3-dioxygenase (IDO) enzymes are differentially expressed in the pulmonary blood vessels, i.e., IDO1 prevails in early/mild pneumonia and in lung tissues from patients suffering from long COVID-19, whereas IDO2 is predominant in severe/fatal cases. We hypothesize that IDO1 is necessary for a correct control of the vascular tone of pulmonary vessels, and its deficiency in COVID-19 might be related to the syndrome's evolution toward vascular dysfunction. The complexity of this scenario is discussed in light of possible therapeutic manipulations of the tryptophan/kynurenine pathway in COVID-19 and post-acute COVID-19 syndromes.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chilosi</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pathology, Pederzoli Hospital, 37019 Peschiera del Garda, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doglioni</LastName><ForeName>Claudio</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-4969-5216</Identifier><AffiliationInfo><Affiliation>Department of Pathology, San Raffaele Scientific Institute, 20132 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ravaglia</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Diseases of the Thorax, Ospedale GB Morgagni, University of Bologna, 47121 Forl&#xec;, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martignoni</LastName><ForeName>Guido</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Pathology, Pederzoli Hospital, 37019 Peschiera del Garda, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Diagnostics, University of Verona, 37134 Verona, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salvagno</LastName><ForeName>Gian Luca</ForeName><Initials>GL</Initials><AffiliationInfo><Affiliation>Section of Clinical Biochemistry, University of Verona, 37134 Verona, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Service of Laboratory Medicine, Pederzoli Hospital, 37019 Peschiera del Garda, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pizzolo</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Medicine, Section of Hematology, University of Verona, 37134 Verona, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bronte</LastName><ForeName>Vincenzo</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Istituto Oncologico Veneto, IOV-IRCCS, 35100 Padova, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poletti</LastName><ForeName>Venerino</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Diseases of the Thorax, Ospedale GB Morgagni, University of Bologna, 47121 Forl&#xec;, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Respiratory Diseases and Allergy, Aarhus University Hospital, 8200 Aarhus, Denmark.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>06</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Biomedicines</MedlineTA><NlmUniqueID>101691304</NlmUniqueID><ISSNLinking>2227-9059</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">IDO</Keyword><Keyword MajorTopicYN="N">PACS</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">post-acute COVID syndrome</Keyword><Keyword MajorTopicYN="N">tryptophan/kynurenine</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>5</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>5</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>6</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>24</Day><Hour>1</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>25</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>6</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35740354</ArticleId><ArticleId IdType="pmc">PMC9220124</ArticleId><ArticleId IdType="doi">10.3390/biomedicines10061332</ArticleId><ArticleId IdType="pii">biomedicines10061332</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., Zhang L., Fan G., Xu J., Gu X., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497&#x2013;506. doi: 10.1016/S0140-6736(20)30183-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30183-5</ArticleId><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Logue J.K., Franko N.M., McCulloch D.J., McDonald D., Magedson A., Wolf C.R., Chu H.Y. Sequelae in Adults at 6 Months after COVID-19 Infection. JAMA Netw. Open. 2021;4:e210830. doi: 10.1001/jamanetworkopen.2021.0830.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.0830</ArticleId><ArticleId IdType="pmc">PMC7896197</ArticleId><ArticleId IdType="pubmed">33606031</ArticleId></ArticleIdList></Reference><Reference><Citation>Darcis G., Bouquegneau A., Maes N., Thys M., Henket M., Labye F., Rousseau A.-F., Canivet P., Desir C., Calmes D., et al. Long-term clinical follow up of patients suffering from moderate to severe COVID-19 infection: A monocentric prospective observational cohort study. Int. J. Infect. Dis. 2021;109:209&#x2013;216. doi: 10.1016/j.ijid.2021.07.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2021.07.016</ArticleId><ArticleId IdType="pmc">PMC8278829</ArticleId><ArticleId IdType="pubmed">34273510</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A., Sehgal K., Gupta A., Madhavan M.V., McGroder C., Stevens J.C., Cook J.R., Nordvig A.S., Shalev D., Sehrawat T.S., et al. Post-acute COVID-19 syndrome. Nat. Med. 2021;27:601&#x2013;615. doi: 10.1038/s41591-021-01283-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Augustin M., Schommers P., Stecher M., Dewald F., Gieselmann L., Gruell H., Horn C., Vanshylla K., Di Cristanziano V., Osebold L., et al. Post-COVID syndrome in non-hospitalised patients with COVID-19: A longitudinal prospective cohort study. Lancet Reg. Health Eur. 2021;6:100122. doi: 10.1016/j.lanepe.2021.100122.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2021.100122</ArticleId><ArticleId IdType="pmc">PMC8129613</ArticleId><ArticleId IdType="pubmed">34027514</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano J.B., Murthy S., Marshall J.C., Relan P., Diaz J.V., WHO Clinical Case Definition Working Group on Post-COVID-19 Condition A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect. Dis. 2022;22:e102&#x2013;e107. doi: 10.1016/S1473-3099(21)00703-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00703-9</ArticleId><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan Z., Yang M., Lai C.L. Long COVID-19 Syndrome: A Comprehensive Review of Its Effect on Various Organ Systems and Recommendation on Rehabilitation Plans. Biomedicines. 2021;9:966. doi: 10.3390/biomedicines9080966.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines9080966</ArticleId><ArticleId IdType="pmc">PMC8394513</ArticleId><ArticleId IdType="pubmed">34440170</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehandru S., Merad M. Pathological sequelae of long-haul COVID. Nat. Immunol. 2022;23:194&#x2013;202. doi: 10.1038/s41590-021-01104-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01104-y</ArticleId><ArticleId IdType="pmc">PMC9127978</ArticleId><ArticleId IdType="pubmed">35105985</ArticleId></ArticleIdList></Reference><Reference><Citation>Antoniou K.M., Vasarmidi E., Russell A.M., Andrejak C., Crestani B., Delcroix M., Dinh-Xuan A.T., Poletti V., Sverzellati N., Vitacca M., et al. European Respiratory Society Statement on Long COVID-19 Follow-Up. Eur. Respir. J. 2022 doi: 10.1183/13993003.02174-2021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.02174-2021</ArticleId><ArticleId IdType="pmc">PMC9349784</ArticleId><ArticleId IdType="pubmed">35144991</ArticleId></ArticleIdList></Reference><Reference><Citation>Carson G., Long Covid Forum Group Research priorities for Long Covid: Refined through an international multi-stakeholder forum. BMC Med. 2021;19:84. doi: 10.1186/s12916-021-01947-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-021-01947-0</ArticleId><ArticleId IdType="pmc">PMC8009733</ArticleId><ArticleId IdType="pubmed">33785027</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhawan R.T., Gopalan D., Howard L., Vicente A., Park M., Manalan K., Wallner I., Marsden P., Dave S., Branley H., et al. Beyond the clot: Perfusion imaging of the pulmonary vasculature after COVID-19. Lancet Respir. Med. 2021;9:107&#x2013;116. doi: 10.1016/S2213-2600(20)30407-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30407-0</ArticleId><ArticleId IdType="pmc">PMC7833494</ArticleId><ArticleId IdType="pubmed">33217366</ArticleId></ArticleIdList></Reference><Reference><Citation>Munblit D., Nicholson T.R., Needham D.M., Seylanova N., Parr C., Chen J., Kokorina A., Sigfrid L., Buonsenso D., Bhatnagar S., et al. Studying the post-COVID-19 condition: Research challenges, strategies and importance of core outcome set development. BMC Med. 2022;20:50. doi: 10.1186/s12916-021-02222-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-021-02222-y</ArticleId><ArticleId IdType="pmc">PMC8813480</ArticleId><ArticleId IdType="pubmed">35114994</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillips S., Williams M.A. Confronting Our Next National Health Disaster&#x2014;Long-Haul Covid. N. Engl. J. Med. 2021;385:577&#x2013;579. doi: 10.1056/NEJMp2109285.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMp2109285</ArticleId><ArticleId IdType="pubmed">34192429</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso M.J., Deitchman A.N., Torres L., Iyer N.S., Munter S.E., Nixon C.C., Donatelli J., Thanh C., Takahashi S., Hakim J., et al. Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptoms. Cell Rep. 2021;36:109518. doi: 10.1016/j.celrep.2021.109518.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2021.109518</ArticleId><ArticleId IdType="pmc">PMC8342976</ArticleId><ArticleId IdType="pubmed">34358460</ArticleId></ArticleIdList></Reference><Reference><Citation>Files J.K., Sarkar S., Fram T.R., Boppana S., Sterrett S., Qin K., Bansal A., Long D.M., Sabbaj S., Kobie J.J., et al. Duration of post-COVID-19 symptoms is associated with sustained SARS-CoV-2-specific immune responses. JCI Insight. 2021;6:e151544. doi: 10.1172/jci.insight.151544.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.151544</ArticleId><ArticleId IdType="pmc">PMC8410022</ArticleId><ArticleId IdType="pubmed">34143754</ArticleId></ArticleIdList></Reference><Reference><Citation>Siemi&#x144;ska I., W&#x119;glarczyk K., Surmiak M., Kurowska-Baran D., Sanak M., Siedlar M., Baran J. Mild and Asymptomatic COVID-19 Convalescents Present Long-Term Endotype of Immunosuppression Associated with Neutrophil Subsets Possessing Regulatory Functions. Front. Immunol. 2021;12:748097. doi: 10.3389/fimmu.2021.748097.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.748097</ArticleId><ArticleId IdType="pmc">PMC8511487</ArticleId><ArticleId IdType="pubmed">34659245</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan F.J., Hope C.M., Masavuli M.G., Lynn M.A., Mekonnen Z.A., Yeow A.E.L., Garcia-Valtanen P., Al-Delfi Z., Gummow J., Ferguson C., et al. Long-term perturbation of the peripheral immune system months after SARS-CoV-2 infection. BMC Med. 2022;20:26. doi: 10.1186/s12916-021-02228-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-021-02228-6</ArticleId><ArticleId IdType="pmc">PMC8758383</ArticleId><ArticleId IdType="pubmed">35027067</ArticleId></ArticleIdList></Reference><Reference><Citation>Theoharides T.C. Could SARS-CoV-2 Spike Protein Be Responsible for Long-COVID Syndrome? Mol. Neurobiol. 2022;59:1850&#x2013;1861. doi: 10.1007/s12035-021-02696-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-021-02696-0</ArticleId><ArticleId IdType="pmc">PMC8757925</ArticleId><ArticleId IdType="pubmed">35028901</ArticleId></ArticleIdList></Reference><Reference><Citation>Ambardar S.R., Hightower S.L., Huprikar N.A., Chung K.K., Singhal A., Collen J.F. Post-COVID-19 Pulmonary Fibrosis: Novel Sequelae of the Current Pandemic. J. Clin. Med. 2021;10:2452. doi: 10.3390/jcm10112452.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10112452</ArticleId><ArticleId IdType="pmc">PMC8199255</ArticleId><ArticleId IdType="pubmed">34205928</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y.M., Shang Y.M., Song W.B., Li Q.Q., Xie H., Xu Q.F., Jia J.L., Li L.M., Mao H.L., Zhou X.M., et al. Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery. EClinicalMedicine. 2020;25:100463. doi: 10.1016/j.eclinm.2020.100463.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2020.100463</ArticleId><ArticleId IdType="pmc">PMC7361108</ArticleId><ArticleId IdType="pubmed">32838236</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z., Xie Y., Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature. 2021;594:259&#x2013;264. doi: 10.1038/s41586-021-03553-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03553-9</ArticleId><ArticleId IdType="pubmed">33887749</ArticleId></ArticleIdList></Reference><Reference><Citation>Daugherty S.E., Guo Y., Heath K., Dasmari&#xf1;as M.C., Jubilo K.G., Samranvedhya J., Lipsitch M., Cohen K. Risk of clinical sequelae after the acute phase of SARS-CoV-2 infection: Retrospective cohort study. BMJ. 2021;373:n1098. doi: 10.1136/bmj.n1098.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n1098</ArticleId><ArticleId IdType="pmc">PMC8132065</ArticleId><ArticleId IdType="pubmed">34011492</ArticleId></ArticleIdList></Reference><Reference><Citation>Goel N., Goyal N., Kumar R. Long COVID Mimicking Interstitial Lung Disease: A Case Series. Curr. Health Sci. J. 2021;47:469&#x2013;473. doi: 10.12865/CHSJ.47.03.22.</Citation><ArticleIdList><ArticleId IdType="doi">10.12865/CHSJ.47.03.22</ArticleId><ArticleId IdType="pmc">PMC8679157</ArticleId><ArticleId IdType="pubmed">35003784</ArticleId></ArticleIdList></Reference><Reference><Citation>Myall K.J., Mukherjee B., Castanheira A.M., Lam J.L., Benedetti G., Mak S.M., Preston R., Thillai M., Dewar A., Molyneaux P.L., et al. Persistent Post-COVID-19 Interstitial Lung Disease. An Observational Study of Corticosteroid Treatment. Ann. Am. Thorac. Soc. 2021;18:799&#x2013;806. doi: 10.1513/AnnalsATS.202008-1002OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1513/AnnalsATS.202008-1002OC</ArticleId><ArticleId IdType="pmc">PMC8086530</ArticleId><ArticleId IdType="pubmed">33433263</ArticleId></ArticleIdList></Reference><Reference><Citation>Aronson K.I., Podolanczuk A.J. Lungs after COVID-19: Evolving Knowledge of Post-COVID-19 Interstitial Lung Disease. Ann. Am. Thorac. Soc. 2021;18:773&#x2013;774. doi: 10.1513/AnnalsATS.202102-223ED.</Citation><ArticleIdList><ArticleId IdType="doi">10.1513/AnnalsATS.202102-223ED</ArticleId><ArticleId IdType="pmc">PMC8086543</ArticleId><ArticleId IdType="pubmed">33929309</ArticleId></ArticleIdList></Reference><Reference><Citation>Mo X., Jian W., Su Z., Chen M., Peng H., Peng P., Lei C., Chen R., Zhong N., Li S. Abnormal pulmonary function in COVID-19 patients at time of hospital discharge. Eur. Respir. J. 2020;55:2001217. doi: 10.1183/13993003.01217-2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.01217-2020</ArticleId><ArticleId IdType="pmc">PMC7236826</ArticleId><ArticleId IdType="pubmed">32381497</ArticleId></ArticleIdList></Reference><Reference><Citation>Daher A., Balfanz P., Cornelissen C., M&#xfc;ller A., Bergs I., Marx N., M&#xfc;ller-Wieland D., Hartmann B., Dreher M., M&#xfc;ller T. Follow up of patients with severe coronavirus disease 2019 (COVID-19): Pulmonary and extrapulmonary disease sequelae. Respir. Med. 2020;174:106197. doi: 10.1016/j.rmed.2020.106197.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rmed.2020.106197</ArticleId><ArticleId IdType="pmc">PMC7573668</ArticleId><ArticleId IdType="pubmed">33120193</ArticleId></ArticleIdList></Reference><Reference><Citation>Van der Sar-Van der Brugge S., Talman S., Boonman-de Winter L.J.M., de Mol M., Hoefman E., van Etten R.W., De Backer I.C. Pulmonary function and health-related quality of life after COVID-19 pneumonia. Respir. Med. 2021;176:106272. doi: 10.1016/j.rmed.2020.106272.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rmed.2020.106272</ArticleId><ArticleId IdType="pmc">PMC7701891</ArticleId><ArticleId IdType="pubmed">33302142</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang L., Yao Q., Gu X., Wang Q., Ren L., Wang Y., Hu P., Guo L., Liu M., Xu J., et al. 1-year outcomes in hospital survivors with COVID-19: A longitudinal cohort study. Lancet. 2021;398:747&#x2013;758. doi: 10.1016/S0140-6736(21)01755-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)01755-4</ArticleId><ArticleId IdType="pmc">PMC8389999</ArticleId><ArticleId IdType="pubmed">34454673</ArticleId></ArticleIdList></Reference><Reference><Citation>Salerno D., Oriaku I., Darnell M., Lanclus M., De Backer J., Lavon B., Gupta R., Jaffe F., Vega Sanchez M.E., Kim V. Temple University Covid-19 Research Group. Association of abnormal pulmonary vasculature on CT scan for COVID-19 infection with decreased diffusion capacity in follow up: A retrospective cohort study. PLoS ONE. 2021;16:e0257892. doi: 10.1371/journal.pone.0257892.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0257892</ArticleId><ArticleId IdType="pmc">PMC8519442</ArticleId><ArticleId IdType="pubmed">34653196</ArticleId></ArticleIdList></Reference><Reference><Citation>Chilosi M., Poletti V., Ravaglia C., Rossi G., Dubini A., Piciucchi S., Pedica F., Bronte V., Pizzolo G., Martignoni G., et al. The pathogenic role of epithelial and endothelial cells in early-phase COVID-19 pneumonia: Victims and partners in crime. Mod. Pathol. 2021;34:1444&#x2013;1455. doi: 10.1038/s41379-021-00808-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41379-021-00808-8</ArticleId><ArticleId IdType="pmc">PMC8058579</ArticleId><ArticleId IdType="pubmed">33883694</ArticleId></ArticleIdList></Reference><Reference><Citation>Oldani S., Ravaglia C., Bensai S., Bertolovic L., Ghirotti C., Puglisi S., Martinello S., Sultani F., Colinelli C., Piciucchi S., et al. Pathophysiology of light phenotype SARS-CoV-2 interstitial pneumonia: From histopathological features to clinical presentations. Pulmonology. 2021 doi: 10.1016/j.pulmoe.2021.03.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pulmoe.2021.03.003</ArticleId><ArticleId IdType="pmc">PMC7997696</ArticleId><ArticleId IdType="pubmed">33832850</ArticleId></ArticleIdList></Reference><Reference><Citation>Santamarina M.G., Beddings I., Lomakin F.M., Boisier Riscal D., Guti&#xe9;rrez Claveria M., Vidal Marambio J., Retamal B&#xe1;ez N., Pavez Novoa C., Reyes Allende C., Ferreira Perey P., et al. Sildenafil for treating patients with COVID-19 and perfusion mismatch: A pilot randomized trial. Crit. Care. 2022;26:1. doi: 10.1186/s13054-021-03885-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-021-03885-y</ArticleId><ArticleId IdType="pmc">PMC8721481</ArticleId><ArticleId IdType="pubmed">34980198</ArticleId></ArticleIdList></Reference><Reference><Citation>Piciucchi S., Ravaglia C., Vizzuso A., Giampalma E., Poletti V. Awake prone positioning for COVID-19 acute respiratory failure: Imaging and histological background. Lancet Respir. Med. 2022;10:e14. doi: 10.1016/S2213-2600(21)00554-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00554-3</ArticleId><ArticleId IdType="pmc">PMC8806195</ArticleId><ArticleId IdType="pubmed">35120610</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravaglia C., Doglioni C., Chilosi M., Piciucchi S., Dubini A., Rossi G., Pedica F., Puglisi S., Donati L., Tomassetti S., et al. Clinical, radiological, and pathological findings in patients with persistent lung disease following SARS-CoV-2 infection. Eur. Respir. J. 2022 doi: 10.1183/13993003.02411-2021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.02411-2021</ArticleId><ArticleId IdType="pmc">PMC8932282</ArticleId><ArticleId IdType="pubmed">35301248</ArticleId></ArticleIdList></Reference><Reference><Citation>Doglioni C., Ravaglia C., Chilosi M., Rossi G., Dubini A., Pedica F., Piciucchi S., Vizzuso A., Stella F., Maitan S., et al. COVID-19 Interstitial Pneumonia: Histological and Immunohistochemical Features on Cryobiopsies. Respiration. 2021;100:488&#x2013;498. doi: 10.1159/000514822.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000514822</ArticleId><ArticleId IdType="pmc">PMC8018216</ArticleId><ArticleId IdType="pubmed">33725700</ArticleId></ArticleIdList></Reference><Reference><Citation>Grifka-Walk H.M., Jenkins B.R., Kominsky D.J. Amino Acid Trp: The Far Out Impacts of Host and Commensal Tryptophan Metabolism. Front. Immunol. 2021;12:653208. doi: 10.3389/fimmu.2021.653208.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.653208</ArticleId><ArticleId IdType="pmc">PMC8213022</ArticleId><ArticleId IdType="pubmed">34149693</ArticleId></ArticleIdList></Reference><Reference><Citation>Leklem J.E. Quantitative aspects of tryptophan metabolism in humans and other species: A review. Am. J. Clin. Nutr. 1971;24:659&#x2013;672. doi: 10.1093/ajcn/24.6.659.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ajcn/24.6.659</ArticleId><ArticleId IdType="pubmed">4253043</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeung A.W., Terentis A.C., King N.J., Thomas S.R. Role of indoleamine 2,3-dioxygenase in health and disease. Clin. Sci. 2015;129:601&#x2013;672. doi: 10.1042/CS20140392.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/CS20140392</ArticleId><ArticleId IdType="pubmed">26186743</ArticleId></ArticleIdList></Reference><Reference><Citation>Badawy A.A. Kynurenine Pathway of Tryptophan Metabolism: Regulatory and Functional Aspects. Int J. Tryptophan Res. 2017;10:1178646917691938. doi: 10.1177/1178646917691938.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1178646917691938</ArticleId><ArticleId IdType="pmc">PMC5398323</ArticleId><ArticleId IdType="pubmed">28469468</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu H., Gong J., Liu Y. Indoleamine 2, 3-dioxygenase regulation of immune response (Review) Mol. Med. Rep. 2018;17:4867&#x2013;4873. doi: 10.3892/mmr.2018.8537.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/mmr.2018.8537</ArticleId><ArticleId IdType="pubmed">29393500</ArticleId></ArticleIdList></Reference><Reference><Citation>Marszalek-Grabska M., Walczak K., Gawel K., Wicha-Komsta K., Wnorowska S., Wnorowski A., Turski W.A. Kynurenine emerges from the shadows&#x2014;Current knowledge on its fate and function. Pharmacol. Ther. 2021;225:107845. doi: 10.1016/j.pharmthera.2021.107845.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pharmthera.2021.107845</ArticleId><ArticleId IdType="pubmed">33831481</ArticleId></ArticleIdList></Reference><Reference><Citation>Ala M. The footprint of kynurenine pathway in every cancer: A new target for chemotherapy. Eur. J. Pharmacol. 2021;896:173921. doi: 10.1016/j.ejphar.2021.173921.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2021.173921</ArticleId><ArticleId IdType="pubmed">33529725</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray H.W., Szuro-Sudol A., Wellner D., Oca M.J., Granger A.M., Libby D.M., Rothermel C.D., Rubin B.Y. Role of tryptophan degradation in respiratory burst-independent antimicrobial activity of gamma interferon-stimulated human macrophages. Infect. Immun. 1989;57:845&#x2013;849. doi: 10.1128/iai.57.3.845-849.1989.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/iai.57.3.845-849.1989</ArticleId><ArticleId IdType="pmc">PMC313187</ArticleId><ArticleId IdType="pubmed">2492973</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlin J.M., Borden E.C., Byrne G.I. Interferon-induced indoleamine 2,3-dioxygenase activity inhibits Chlamydia psittaci replication in human macrophages. J. Interferon Res. 1989;9:329&#x2013;337. doi: 10.1089/jir.1989.9.329.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/jir.1989.9.329</ArticleId><ArticleId IdType="pubmed">2501398</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams O., Besken K., Oberd&#xf6;rfer C., MacKenzie C.R., Takikawa O., D&#xe4;ubener W. Role of indoleamine-2,3-dioxygenase in alpha/beta and gamma interferon-mediated antiviral effects against herpes simplex virus infections. J. Virol. 2004;78:2632&#x2013;2636. doi: 10.1128/JVI.78.5.2632-2636.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.78.5.2632-2636.2004</ArticleId><ArticleId IdType="pmc">PMC369218</ArticleId><ArticleId IdType="pubmed">14963171</ArticleId></ArticleIdList></Reference><Reference><Citation>Grohmann U., Bronnte V. Control of immune response by amino acid metabolism. Immunol. Rev. 2010;236:243&#x2013;264. doi: 10.1111/j.1600-065X.2010.00915.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-065X.2010.00915.x</ArticleId><ArticleId IdType="pubmed">20636821</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray P.J. Amino acid auxotrophy as a system of immunological control nodes. Nat. Immunol. 2016;17:132&#x2013;139. doi: 10.1038/ni.3323.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.3323</ArticleId><ArticleId IdType="pmc">PMC4893777</ArticleId><ArticleId IdType="pubmed">26784254</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto S., Hayaishi O. Tryptophan pyrrolase of rabbit intestine. D- and L-tryptophan-cleaving enzyme or enzymes. J. Biol. Chem. 1967;242:5260&#x2013;5266. doi: 10.1016/S0021-9258(18)99420-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0021-9258(18)99420-2</ArticleId><ArticleId IdType="pubmed">6065097</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuasa H.J., Takubo M., Takahashi A., Hasegawa T., Noma H., Suzuki T. Evolution of vertebrate indoleamine 2,3-dioxygenases. J. Mol. Evol. 2007;65:705&#x2013;714. doi: 10.1007/s00239-007-9049-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00239-007-9049-1</ArticleId><ArticleId IdType="pubmed">18026683</ArticleId></ArticleIdList></Reference><Reference><Citation>Ball H.J., Sanchez-Perez A., Weiser S., Austin C.J., Astelbauer F., Miu J., McQuillan J.A., Stocker R., Jermiin L.S., Hunt N.H. Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice. Gene. 2007;396:203&#x2013;213. doi: 10.1016/j.gene.2007.04.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gene.2007.04.010</ArticleId><ArticleId IdType="pubmed">17499941</ArticleId></ArticleIdList></Reference><Reference><Citation>Meininger D., Zalameda L., Liu Y., Stepan L.P., Borges L., McCarter J.D., Sutherland C.L. Purification and kinetic characterization of human indoleamine 2,3-dioxygenases 1 and 2 (IDO1 and IDO2) and discovery of selective IDO1 inhibitors. Biochim. Biophys. Acta. 2011;1814:1947&#x2013;1954. doi: 10.1016/j.bbapap.2011.07.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbapap.2011.07.023</ArticleId><ArticleId IdType="pubmed">21835273</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfefferkorn E.R., Rebhun S., Eckel M. Characterization of an indoleamine 2,3-dioxygenase induced by gamma-interferon in cultured human fibroblasts. J. Interferon Res. 1986;6:267&#x2013;279. doi: 10.1089/jir.1986.6.267.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/jir.1986.6.267</ArticleId><ArticleId IdType="pubmed">2427623</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor M.W., Feng G.S. Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J. 1991;5:2516&#x2013;2522. doi: 10.1096/fasebj.5.11.1907934.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fasebj.5.11.1907934</ArticleId><ArticleId IdType="pubmed">1907934</ArticleId></ArticleIdList></Reference><Reference><Citation>Liebau C., Baltzer A.W., Schmidt S., Roesel C., Karreman C., Prisack J.B., Bojar H., Merk H. Interleukin-12 and interleukin-18 induce indoleamine 2,3-dioxygenase (IDO) activity in human osteosarcoma cell lines independently from interferon-gamma. Anticancer Res. 2002;22:931&#x2013;936.</Citation><ArticleIdList><ArticleId IdType="pubmed">12014674</ArticleId></ArticleIdList></Reference><Reference><Citation>Poljak A., Grant R., Austin C.J., Jamie J.F., Willows R.D., Takikawa O., Littlejohn T.K., Truscott R.J., Walker M.J., Sachdev P., et al. Inhibition of indoleamine 2,3 dioxygenase activity by H2O2. Arch. Biochem. Biophys. 2006;450:9&#x2013;19. doi: 10.1016/j.abb.2006.03.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.abb.2006.03.003</ArticleId><ArticleId IdType="pubmed">16624246</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas S.R., Terentis A.C., Cai H., Takikawa O., Levina A., Lay P.A., Freewan M., Stocker R. Post-translational regulation of human indoleamine 2,3-dioxygenase activity by nitric oxide. J. Biol. Chem. 2007;282:23778&#x2013;23787. doi: 10.1074/jbc.M700669200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M700669200</ArticleId><ArticleId IdType="pubmed">17535808</ArticleId></ArticleIdList></Reference><Reference><Citation>Orabona C., Pallotta M.T., Volpi C., Fallarino F., Vacca C., Bianchi R., Belladonna M.L., Fioretti M.C., Grohmann U., Puccetti P. SOCS3 drives proteasomal degradation of indoleamine 2,3-dioxygenase (IDO) and antagonizes IDO-dependent tolerogenesis. Proc. Natl. Acad. Sci. USA. 2008;105:20828&#x2013;20833. doi: 10.1073/pnas.0810278105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0810278105</ArticleId><ArticleId IdType="pmc">PMC2634889</ArticleId><ArticleId IdType="pubmed">19088199</ArticleId></ArticleIdList></Reference><Reference><Citation>Munn D.H., Sharma M.D., Baban B., Harding H.P., Zhang Y., Ron D., Mellor A.L. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity. 2005;22:633&#x2013;642. doi: 10.1016/j.immuni.2005.03.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2005.03.013</ArticleId><ArticleId IdType="pubmed">15894280</ArticleId></ArticleIdList></Reference><Reference><Citation>Sundrud M.S., Koralov S.B., Feuerer M., Calado D.P., Kozhaya A.E., Rhule-Smith A., Lefebvre R.E., Unutmaz D., Mazitschek R., Waldner H., et al. Halofuginone inhibits TH17 cell differentiation by activating the amino acid starvation response. Science. 2009;324:1334&#x2013;1338. doi: 10.1126/science.1172638.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1172638</ArticleId><ArticleId IdType="pmc">PMC2803727</ArticleId><ArticleId IdType="pubmed">19498172</ArticleId></ArticleIdList></Reference><Reference><Citation>Biswas M., Sarkar D., Kumar S.R., Nayak S., Rogers G.L., Markusic D.M., Liao G., Terhorst C., Herzog R.W. Synergy between rapamycin and FLT3 ligand enhances plasmacytoid dendritic cell-dependent induction of CD4+CD25+FoxP3+Treg. Blood. 2015;125:2937&#x2013;2947. doi: 10.1182/blood-2014-09-599266.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2014-09-599266</ArticleId><ArticleId IdType="pmc">PMC4424416</ArticleId><ArticleId IdType="pubmed">25833958</ArticleId></ArticleIdList></Reference><Reference><Citation>Turnquist H.R., Raimondi G., Zahorchak A.F., Fischer R.T., Wang Z., Thomson A.W. Rapamycin-conditioned dendritic cells are poor stimulators of allogeneic CD4+ T cells, but enrich for antigen-specific Foxp3+ T regulatory cells and promote organ transplant tolerance. J. Immunol. 2007;178:7018&#x2013;7031. doi: 10.4049/jimmunol.178.11.7018.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.178.11.7018</ArticleId><ArticleId IdType="pubmed">17513751</ArticleId></ArticleIdList></Reference><Reference><Citation>Mezrich J.D., Fechner J.H., Zhang X., Johnson B.P., Burlingham W.J., Bradfield C.A. An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J. Immunol. 2010;185:3190&#x2013;3198. doi: 10.4049/jimmunol.0903670.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.0903670</ArticleId><ArticleId IdType="pmc">PMC2952546</ArticleId><ArticleId IdType="pubmed">20720200</ArticleId></ArticleIdList></Reference><Reference><Citation>Torti M.F., Giovannoni F., Quintana F.J., Garc&#xed;a C.C. The Aryl Hydrocarbon Receptor as a Modulator of Anti-viral Immunity. Front. Immunol. 2021;12:624293. doi: 10.3389/fimmu.2021.624293.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.624293</ArticleId><ArticleId IdType="pmc">PMC7973006</ArticleId><ArticleId IdType="pubmed">33746961</ArticleId></ArticleIdList></Reference><Reference><Citation>Guarnieri T., Abruzzo P.M., Bolotta A. More than a cell biosensor: Aryl hydrocarbon receptor at the intersection of physiology and inflammation. Am. J. Physiol.-Cell Physiol. 2020;318:C1078&#x2013;C1082. doi: 10.1152/ajpcell.00493.2019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpcell.00493.2019</ArticleId><ArticleId IdType="pubmed">32208988</ArticleId></ArticleIdList></Reference><Reference><Citation>Bessede A., Gargaro M., Pallotta M.T., Matino D., Servillo G., Brunacci C., Bicciato S., Mazza E.M., Macchiarulo A., Vacca C., et al. Aryl hydrocarbon receptor control of a disease tolerance defence pathway. Nature. 2014;511:184&#x2013;190. doi: 10.1038/nature13323.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature13323</ArticleId><ArticleId IdType="pmc">PMC4098076</ArticleId><ArticleId IdType="pubmed">24930766</ArticleId></ArticleIdList></Reference><Reference><Citation>Denison M.S., Pandini A., Nagy S.R., Baldwin E.P., Bonati L. Ligand binding and activation of the Ah receptor. Chem. Biol. Interact. 2002;141:3&#x2013;24. doi: 10.1016/S0009-2797(02)00063-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0009-2797(02)00063-7</ArticleId><ArticleId IdType="pubmed">12213382</ArticleId></ArticleIdList></Reference><Reference><Citation>Quintana F.J., Basso A.S., Iglesias A.H., Korn T., Farez M.F., Bettelli E., Caccamo M., Oukka M., Weiner H.L. Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor. Nature. 2008;453:65&#x2013;71. doi: 10.1038/nature06880.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature06880</ArticleId><ArticleId IdType="pubmed">18362915</ArticleId></ArticleIdList></Reference><Reference><Citation>Grohmann U., Puccetti P. The Coevolution of IDO1 and AhR in the Emergence of Regulatory T-Cells in Mammals. Front. Immunol. 2015;6:58. doi: 10.3389/fimmu.2015.00058.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2015.00058</ArticleId><ArticleId IdType="pmc">PMC4325913</ArticleId><ArticleId IdType="pubmed">25729384</ArticleId></ArticleIdList></Reference><Reference><Citation>Mondanelli G., Bianchi R., Pallotta M.T., Orabona C., Albini E., Iacono A., Belladonna M.L., Vacca C., Fallarino F., Macchiarulo A., et al. A Relay Pathway between Arginine and Tryptophan Metabolism Confers Immunosuppressive Properties on Dendritic Cells. Immunity. 2017;46:233&#x2013;244. doi: 10.1016/j.immuni.2017.01.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2017.01.005</ArticleId><ArticleId IdType="pmc">PMC5337620</ArticleId><ArticleId IdType="pubmed">28214225</ArticleId></ArticleIdList></Reference><Reference><Citation>Orabona C., Pallotta M.T., Grohmann U. Different partners, opposite outcomes: A new perspective of the immunobiology of indoleamine 2,3-dioxygenase. Mol. Med. 2012;18:834&#x2013;842. doi: 10.2119/molmed.2012.00029.</Citation><ArticleIdList><ArticleId IdType="doi">10.2119/molmed.2012.00029</ArticleId><ArticleId IdType="pmc">PMC3409287</ArticleId><ArticleId IdType="pubmed">22481272</ArticleId></ArticleIdList></Reference><Reference><Citation>Grohmann U., Fallarino F., Bianchi R., Belladonna M.L., Vacca C., Orabona C., Uyttenhove C., Fioretti M.C., Puccetti P. IL-6 inhibits the tolerogenic function of CD8 alpha+ dendritic cells expressing indoleamine 2,3-dioxygenase. J. Immunol. 2001;167:708&#x2013;714. doi: 10.4049/jimmunol.167.2.708.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.167.2.708</ArticleId><ArticleId IdType="pubmed">11441074</ArticleId></ArticleIdList></Reference><Reference><Citation>Fallarino F., Grohmann U., Puccetti P. Indoleamine 2,3-dioxygenase: From catalyst to signaling function. Eur. J. Immunol. 2012;42:1932&#x2013;1937. doi: 10.1002/eji.201242572.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.201242572</ArticleId><ArticleId IdType="pubmed">22865044</ArticleId></ArticleIdList></Reference><Reference><Citation>Belladonna M.L., Volpi C., Bianchi R., Vacca C., Orabona C., Pallotta M.T., Boon L., Gizzi S., Fioretti M.C., Grohmann U., et al. Cutting edge: Autocrine TGF-beta sustains default tolerogenesis by IDO-competent dendritic cells. J. Immunol. 2008;181:5194&#x2013;5198. doi: 10.4049/jimmunol.181.8.5194.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.181.8.5194</ArticleId><ArticleId IdType="pubmed">18832670</ArticleId></ArticleIdList></Reference><Reference><Citation>Albini E., Rosini V., Gargaro M., Mondanelli G., Belladonna M.L., Pallotta M.T., Volpi C., Fallarino F., Macchiarulo A., Antognelli C., et al. Distinct roles of immunoreceptor tyrosine-based motifs in immunosuppressive indoleamine 2,3-dioxygenase 1. J. Cell. Mol. Med. 2017;21:165&#x2013;176. doi: 10.1111/jcmm.12954.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jcmm.12954</ArticleId><ArticleId IdType="pmc">PMC5192792</ArticleId><ArticleId IdType="pubmed">27696702</ArticleId></ArticleIdList></Reference><Reference><Citation>Litzenburger U.M., Opitz C.A., Sahm F., Rauschenbach K.J., Trump S., Winter M., Ott M., Ochs K., Lutz C., Liu X., et al. Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR. Oncotarget. 2014;5:1038&#x2013;1051. doi: 10.18632/oncotarget.1637.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.1637</ArticleId><ArticleId IdType="pmc">PMC4011581</ArticleId><ArticleId IdType="pubmed">24657910</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuasa H.J., Mizuno K., Ball H.J. Low efficiency IDO2 enzymes are conserved in lower vertebrates, whereas higher efficiency IDO1 enzymes are dispensable. FEBS J. 2015;282:2735&#x2013;2745. doi: 10.1111/febs.13316.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/febs.13316</ArticleId><ArticleId IdType="pubmed">25950090</ArticleId></ArticleIdList></Reference><Reference><Citation>Munn D.H., Zhou M., Attwood J.T., Bondarev I., Conway S.J., Marshall B., Brown C., Mellor A.L. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science. 1998;281:1191&#x2013;1193. doi: 10.1126/science.281.5380.1191.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.281.5380.1191</ArticleId><ArticleId IdType="pubmed">9712583</ArticleId></ArticleIdList></Reference><Reference><Citation>Ball H.J., Jusof F.F., Bakmiwewa S.M., Hunt N.H., Yuasa H.J. Tryptophan-catabolizing enzymes&#x2014;Party of three. Front. Immunol. 2014;5:485. doi: 10.3389/fimmu.2014.00485.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2014.00485</ArticleId><ArticleId IdType="pmc">PMC4191572</ArticleId><ArticleId IdType="pubmed">25346733</ArticleId></ArticleIdList></Reference><Reference><Citation>Merlo L.M.F., Pigott E., DuHadaway J.B., Grabler S., Metz R., Prendergast G.C., Mandik-Nayak L. IDO2 is a critical mediator of autoantibody production and inflammatory pathogenesis in a mouse model of autoimmune arthritis. J. Immunol. 2014;192:2082&#x2013;2090. doi: 10.4049/jimmunol.1303012.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1303012</ArticleId><ArticleId IdType="pmc">PMC3947779</ArticleId><ArticleId IdType="pubmed">24489090</ArticleId></ArticleIdList></Reference><Reference><Citation>Merlo L.M., Mandik-Nayak L. IDO2: A Pathogenic Mediator of Inflammatory Autoimmunity. Clin. Med. Insights Pathol. 2016;9:21&#x2013;28. doi: 10.4137/CPath.S39930.</Citation><ArticleIdList><ArticleId IdType="doi">10.4137/CPath.S39930</ArticleId><ArticleId IdType="pmc">PMC5119657</ArticleId><ArticleId IdType="pubmed">27891058</ArticleId></ArticleIdList></Reference><Reference><Citation>Merlo L.M.F., DuHadaway J.B., Montgomery J.D., Peng W.D., Murray P.J., Prendergast G.C., Caton A.J., Muller A.J., Mandik-Nayak L. Differential Roles of IDO1 and IDO2 in T and B Cell Inflammatory Immune Responses. Front. Immunol. 2020;11:1861. doi: 10.3389/fimmu.2020.01861.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.01861</ArticleId><ArticleId IdType="pmc">PMC7461966</ArticleId><ArticleId IdType="pubmed">32973768</ArticleId></ArticleIdList></Reference><Reference><Citation>Merlo L.M.F., Peng W., DuHadaway J.B., Montgomery J.D., Prendergast G.C., Muller A.J., Mandik-Nayak L. The Immunomodulatory Enzyme IDO2 Mediates Autoimmune Arthritis through a Nonenzymatic Mechanism. J. Immunol. 2022;208:571&#x2013;581. doi: 10.4049/jimmunol.2100705.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.2100705</ArticleId><ArticleId IdType="pmc">PMC8770583</ArticleId><ArticleId IdType="pubmed">34965962</ArticleId></ArticleIdList></Reference><Reference><Citation>Fatokun A.A., Hunt N.H., Ball H.J. Indoleamine 2,3-dioxygenase 2 (IDO2) and the kynurenine pathway: Characteristics and potential roles in health and disease. Amino Acids. 2013;45:1319&#x2013;1329. doi: 10.1007/s00726-013-1602-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00726-013-1602-1</ArticleId><ArticleId IdType="pubmed">24105077</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoshi M., Osawa Y., Nakamoto K., Morita N., Yamamoto Y., Ando T., Tashita C., Nabeshima T., Saito K. Kynurenine produced by indoleamine 2,3-dioxygenase 2 exacerbates acute liver injury by carbon tetrachloride in mice. Toxicology. 2020;438:152458. doi: 10.1016/j.tox.2020.152458.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tox.2020.152458</ArticleId><ArticleId IdType="pubmed">32289347</ArticleId></ArticleIdList></Reference><Reference><Citation>Pantouris G., Serys M., Yuasa H.J., Ball H.J., Mowat C.G. Human indoleamine 2,3-dioxygenase-2 has substrate specificity and inhibition characteristics distinct from those of indoleamine 2,3-dioxygenase-1. Amino Acids. 2014;46:2155&#x2013;2163. doi: 10.1007/s00726-014-1766-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00726-014-1766-3</ArticleId><ArticleId IdType="pubmed">24875753</ArticleId></ArticleIdList></Reference><Reference><Citation>Mondanelli G., Mandarano M., Belladonna M.L., Suvieri C., Pelliccia C., Bellezza G., Sidoni A., Carvalho A., Grohmann U., Volpi C. Current Challenges for IDO2 as Target in Cancer Immunotherapy. Front. Immunol. 2021;12:679953. doi: 10.3389/fimmu.2021.679953.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.679953</ArticleId><ArticleId IdType="pmc">PMC8097162</ArticleId><ArticleId IdType="pubmed">33968089</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy J.M., Mace P.D., Eyers P.A. Live and let die: Insights into pseudoenzyme mechanisms from structure. Curr. Opin. Struct. Biol. 2017;47:95&#x2013;104. doi: 10.1016/j.sbi.2017.07.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sbi.2017.07.004</ArticleId><ArticleId IdType="pubmed">28787627</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy J.M., Farhan H., Eyers P.A. Bio-Zombie: The rise of pseudoenzymes in biology. Biochem. Soc. Trans. 2017;45:537&#x2013;544. doi: 10.1042/BST20160400.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BST20160400</ArticleId><ArticleId IdType="pubmed">28408493</ArticleId></ArticleIdList></Reference><Reference><Citation>Adrain C. Pseudoenzymes: Dead enzymes with a lively role in biology. FEBS J. 2020;287:4102&#x2013;4105. doi: 10.1111/febs.15535.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/febs.15535</ArticleId><ArticleId IdType="pubmed">33026715</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q., Harden J.L., Anderson C.D., Egilmez N.K. Tolerogenic Phenotype of IFN-&#x3b3;-Induced IDO+ Dendritic Cells Is Maintained via an Autocrine IDO-Kynurenine/AhR-IDO Loop. J. Immunol. 2016;197:962&#x2013;970. doi: 10.4049/jimmunol.1502615.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1502615</ArticleId><ArticleId IdType="pubmed">27316681</ArticleId></ArticleIdList></Reference><Reference><Citation>Hofmann F. Ido brings down the pressure in systemic inflammation. Nat. Med. 2010;16:265&#x2013;267. doi: 10.1038/nm0310-265.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm0310-265</ArticleId><ArticleId IdType="pubmed">20208509</ArticleId></ArticleIdList></Reference><Reference><Citation>Stone T.W., Forrest C.M., Darlington L.G. Kynurenine pathway inhibition as a therapeutic strategy for neuroprotection. FEBS J. 2012;279:1386&#x2013;1397. doi: 10.1111/j.1742-4658.2012.08487.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1742-4658.2012.08487.x</ArticleId><ArticleId IdType="pubmed">22248239</ArticleId></ArticleIdList></Reference><Reference><Citation>Lovelace M.D., Varney B., Sundaram G., Lennon M.J., Lim C.K., Jacobs K., Guillemin G.J., Brew B.J. Recent evidence for an expanded role of the kynurenine pathway of tryptophan metabolism in neurological diseases. Neuropharmacology. 2017;112:373&#x2013;388. doi: 10.1016/j.neuropharm.2016.03.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2016.03.024</ArticleId><ArticleId IdType="pubmed">26995730</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwarcz R., Stone T.W. The kynurenine pathway and the brain: Challenges, controversies and promises. Neuropharmacology. 2017;112:237&#x2013;247. doi: 10.1016/j.neuropharm.2016.08.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2016.08.003</ArticleId><ArticleId IdType="pmc">PMC5803785</ArticleId><ArticleId IdType="pubmed">27511838</ArticleId></ArticleIdList></Reference><Reference><Citation>Opitz C.A., Somarribas Patterson L.F., Mohapatra S.R., Dewi D.L., Sadik A., Platten M., Trump S. The therapeutic potential of targeting tryptophan catabolism in cancer. Br. J. Cancer. 2020;122:30&#x2013;44. doi: 10.1038/s41416-019-0664-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41416-019-0664-6</ArticleId><ArticleId IdType="pmc">PMC6964670</ArticleId><ArticleId IdType="pubmed">31819194</ArticleId></ArticleIdList></Reference><Reference><Citation>Theofylaktopoulou D., Midttun &#xd8;., Ulvik A., Ueland P.M., Tell G.S., Vollset S.E., Nyg&#xe5;rd O., Eussen S.J. A community-based study on determinants of circulating markers of cellular immune activation and kynurenines: The Hordaland Health Study. Clin. Exp. Immunol. 2013;173:121&#x2013;130. doi: 10.1111/cei.12092.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cei.12092</ArticleId><ArticleId IdType="pmc">PMC3694542</ArticleId><ArticleId IdType="pubmed">23607723</ArticleId></ArticleIdList></Reference><Reference><Citation>Geisler S., Mayersbach P., Becker K., Schennach H., Fuchs D., Gostner J.M. Serum tryptophan, kynurenine, phenylalanine, tyrosine and neopterin concentrations in 100 healthy blood donors. Pteridines. 2015;26:31&#x2013;36. doi: 10.1515/pterid-2014-0015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/pterid-2014-0015</ArticleId></ArticleIdList></Reference><Reference><Citation>Abedi S., Vessal M., Asadian F., Takhshid M.A. Association of serum kynurenine/tryptophan ratio with poor glycemic control in patients with type2 diabetes. J. Diabetes Metab. Disord. 2021;20:1521&#x2013;1527. doi: 10.1007/s40200-021-00895-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40200-021-00895-z</ArticleId><ArticleId IdType="pmc">PMC8630152</ArticleId><ArticleId IdType="pubmed">34900804</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo H., Ueland P.M., Ulvik A., Eussen S.J., Vollset S.E., Nyg&#xe5;rd O., Midttun &#xd8;., Theofylaktopoulou D., Meyer K., Tell G.S. Plasma Biomarkers of Inflammation, the Kynurenine Pathway and Risks of All-Cause, Cancer and Cardiovascular Disease Mortality: The Hordaland Health Study. Am. J. Epidemiol. 2016;183:249&#x2013;258. doi: 10.1093/aje/kwv242.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwv242</ArticleId><ArticleId IdType="pmc">PMC4753283</ArticleId><ArticleId IdType="pubmed">26823439</ArticleId></ArticleIdList></Reference><Reference><Citation>Pizzini A., Kurz K., Santifaller J., Tschurtschenthaler C., Theurl I., Fuchs D., Weiss G., Bellmann-Weiler R. Assessment of neopterin and indoleamine 2,3-dioxygenase activity in patients with seasonal influenza: A pilot study. Influenza Other Respir. Viruses. 2019;13:603&#x2013;609. doi: 10.1111/irv.12677.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/irv.12677</ArticleId><ArticleId IdType="pmc">PMC6800299</ArticleId><ArticleId IdType="pubmed">31489989</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer K., Patra T., Vijayamahantesh R.R. SARS-CoV-2 Spike Protein Induces Paracrine Senescence and Leukocyte Adhesion in Endothelial Cells. J. Virol. 2021;95:e0079421. doi: 10.1128/JVI.00794-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00794-21</ArticleId><ArticleId IdType="pmc">PMC8354225</ArticleId><ArticleId IdType="pubmed">34160250</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M., Dong X., Huang Y., Su J., Dai X., Guo Y., Hu C., Zhou Q., Zhu B. Activation of the kynurenine pathway is associated with poor outcome in Pneumocystis pneumonia patients infected with HIV: Results of 2&#x2009;months cohort study. BMC Infect. Dis. 2019;19:223. doi: 10.1186/s12879-019-3851-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-019-3851-4</ArticleId><ArticleId IdType="pmc">PMC6399927</ArticleId><ArticleId IdType="pubmed">30832615</ArticleId></ArticleIdList></Reference><Reference><Citation>Adu-Gyamfi C.G., Snyman T., Hoffmann C.J., Martinson N.A., Chaisson R.E., George J.A., Suchard M.S. Plasma Indoleamine 2, 3-Dioxygenase, a Biomarker for Tuberculosis in Human Immunodeficiency Virus-Infected Patients. Clin. Infect. Dis. 2017;65:1356&#x2013;1358. doi: 10.1093/cid/cix550.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/cix550</ArticleId><ArticleId IdType="pmc">PMC5848309</ArticleId><ArticleId IdType="pubmed">29017244</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki Y., Suda T., Asada K., Miwa S., Suzuki M., Fujie M., Furuhashi K., Nakamura Y., Inui N., Shirai T., et al. Serum indoleamine 2,3-dioxygenase activity predicts prognosis of pulmonary tuberculosis. Clin. Vaccine Immunol. 2012;19:436&#x2013;442. doi: 10.1128/CVI.05402-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CVI.05402-11</ArticleId><ArticleId IdType="pmc">PMC3294601</ArticleId><ArticleId IdType="pubmed">22219312</ArticleId></ArticleIdList></Reference><Reference><Citation>Meloni F., Giuliano S., Solari N., Draghi P., Miserere S., Bardoni A.M., Salvini R., Bini F., Fietta A.M. Indoleamine 2,3-dioxygenase in lung allograft tolerance. J. Heart Lung Transplant. 2009;28:1185&#x2013;1192. doi: 10.1016/j.healun.2009.07.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.healun.2009.07.023</ArticleId><ArticleId IdType="pubmed">19783182</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer K.C., Arend R.A., Kalayoglu M.V., Rosenthal N.S., Byrne G.I., Brown R.R. Tryptophan metabolism in chronic inflammatory lung disease. J. Lab. Clin. Med. 1995;126:530&#x2013;540.</Citation><ArticleIdList><ArticleId IdType="pubmed">7490512</ArticleId></ArticleIdList></Reference><Reference><Citation>Odler B., Foris V., Gungl A., M&#xfc;ller V., Hassoun P.M., Kwapiszewska G., Olschewski H., Kovacs G. Biomarkers for Pulmonary Vascular Remodeling in Systemic Sclerosis: A Pathophysiological Approach. Front. Physiol. 2018;9:587. doi: 10.3389/fphys.2018.00587.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphys.2018.00587</ArticleId><ArticleId IdType="pmc">PMC6018494</ArticleId><ArticleId IdType="pubmed">29971007</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki Y., Suda T., Furuhashi K., Suzuki M., Fujie M., Hahimoto D., Nakamura Y., Inui N., Nakamura H., Chida K. Increased serum kynurenine/tryptophan ratio correlates with disease progression in lung cancer. Lung Cancer. 2010;67:361&#x2013;365. doi: 10.1016/j.lungcan.2009.05.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lungcan.2009.05.001</ArticleId><ArticleId IdType="pubmed">19487045</ArticleId></ArticleIdList></Reference><Reference><Citation>Murakami Y., Hoshi M., Imamura Y., Arioka Y., Yamamoto Y., Saito K. Remarkable role of indoleamine 2,3-dioxygenase and tryptophan metabolites in infectious diseases: Potential role in macrophage-mediated inflammatory diseases. Mediat. Inflamm. 2013;2013:391984. doi: 10.1155/2013/391984.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2013/391984</ArticleId><ArticleId IdType="pmc">PMC3588179</ArticleId><ArticleId IdType="pubmed">23476103</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawada L., Vallinoto A.C.R., Brasil-Costa I. Regulation of the Immune Checkpoint Indoleamine 2,3-Dioxygenase Expression by Epstein-Barr Virus. Biomolecules. 2021;11:1792. doi: 10.3390/biom11121792.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom11121792</ArticleId><ArticleId IdType="pmc">PMC8699098</ArticleId><ArticleId IdType="pubmed">34944437</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu P., Chen D., Ding W., Wu P., Hou H., Bai Y., Zhou Y., Li K., Xiang S., Liu P., et al. The trans-omics landscape of COVID-19. Nat. Commun. 2021;12:4543. doi: 10.1038/s41467-021-24482-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-24482-1</ArticleId><ArticleId IdType="pmc">PMC8316550</ArticleId><ArticleId IdType="pubmed">34315889</ArticleId></ArticleIdList></Reference><Reference><Citation>Ansone L., Briviba M., Silamikelis I., Terentjeva A., Perkons I., Birzniece L., Rovite V., Rozentale B., Viksna L., Kolesova O., et al. Amino Acid Metabolism is Significantly Altered at the Time of Admission in Hospital for Severe COVID-19 Patients: Findings from Longitudinal Targeted Metabolomics Analysis. Microbiol. Spectr. 2021;9:e0033821. doi: 10.1128/spectrum.00338-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/spectrum.00338-21</ArticleId><ArticleId IdType="pmc">PMC8653833</ArticleId><ArticleId IdType="pubmed">34878333</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai Y., Kim D.J., Takahashi T., Broadhurst D.I., Yan H., Ma S., Rattray N.J.W., Casanovas-Massana A., Israelow B., Klein J., et al. Kynurenic acid may underlie sex-specific immune responses to COVID-19. Sci. Signal. 2021;14:eabf8483. doi: 10.1126/scisignal.abf8483.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scisignal.abf8483</ArticleId><ArticleId IdType="pmc">PMC8432948</ArticleId><ArticleId IdType="pubmed">34230210</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Alessandro A., Thomas T., Akpan I.J., Reisz J.A., Cendali F.I., Gamboni F., Nemkov T., Thangaraju K., Katneni U., Tanaka K., et al. Biological and Clinical Factors Contributing to the Metabolic Heterogeneity of Hospitalized Patients with and without COVID-19. Cells. 2021;10:2293. doi: 10.3390/cells10092293.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10092293</ArticleId><ArticleId IdType="pmc">PMC8467961</ArticleId><ArticleId IdType="pubmed">34571942</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Amora P., Silva I.D.C.G., Budib M.A., Ayache R., Silva R.M.S., Silva F.C., Appel R.M., J&#xfa;nior S.S., Pontes H.B.D., Alvarenga A.C., et al. Towards risk stratification and prediction of disease severity and mortality in COVID-19: Next generation metabolomics for the measurement of host response to COVID-19 infection. PLoS ONE. 2021;16:e0259909. doi: 10.1371/journal.pone.0259909.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0259909</ArticleId><ArticleId IdType="pmc">PMC8635335</ArticleId><ArticleId IdType="pubmed">34851990</ArticleId></ArticleIdList></Reference><Reference><Citation>Danlos F.X., Grajeda-Iglesias C., Durand S., Sauvat A., Roumier M., Cantin D., Colomba E., Rohmer J., Pommeret F., Baciarello G., et al. Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers. Cell Death Dis. 2021;12:258. doi: 10.1038/s41419-021-03540-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-021-03540-y</ArticleId><ArticleId IdType="pmc">PMC7948172</ArticleId><ArticleId IdType="pubmed">33707411</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawler N.G., Gray N., Kimhofer T., Boughton B., Gay M., Yang R., Morillon A.C., Chin S.T., Ryan M., Begum S., et al. Systemic Perturbations in Amine and Kynurenine Metabolism Associated with Acute SARS-CoV-2 Infection and Inflammatory Cytokine Responses. J. Proteome Res. 2021;20:2796&#x2013;2811. doi: 10.1021/acs.jproteome.1c00052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jproteome.1c00052</ArticleId><ArticleId IdType="pubmed">33724837</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasan M.R., Suleiman M., P&#xe9;rez-L&#xf3;pez A. Metabolomics in the Diagnosis and Prognosis of COVID-19. Front. Genet. 2021;12:721556. doi: 10.3389/fgene.2021.721556.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fgene.2021.721556</ArticleId><ArticleId IdType="pmc">PMC8343128</ArticleId><ArticleId IdType="pubmed">34367265</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao N., Nie M., Pang H., Wang B., Hu J., Meng X., Li K., Ran X., Long Q., Deng H., et al. Integrated cytokine and metabolite analysis reveals immunometabolic reprogramming in COVID-19 patients with therapeutic implications. Nat. Commun. 2021;12:1618. doi: 10.1038/s41467-021-21907-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-21907-9</ArticleId><ArticleId IdType="pmc">PMC7955129</ArticleId><ArticleId IdType="pubmed">33712622</ArticleId></ArticleIdList></Reference><Reference><Citation>Blasco H., Bessy C., Plantier L., Lefevre A., Piver E., Bernard L., Marlet J., Stefic K., Benz-de Bretagne I., Cannet P., et al. The specific metabolome profiling of patients infected by SARS-COV-2 supports the key role of tryptophan-nicotinamide pathway and cytosine metabolism. Sci. Rep. 2020;10:16824. doi: 10.1038/s41598-020-73966-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-73966-5</ArticleId><ArticleId IdType="pmc">PMC7544910</ArticleId><ArticleId IdType="pubmed">33033346</ArticleId></ArticleIdList></Reference><Reference><Citation>Mangge H., Herrmann M., Meinitzer A., Pailer S., Curcic P., Sloup Z., Holter M., Pr&#xfc;ller F. Increased Kynurenine Indicates a Fatal Course of COVID-19. Antioxidants. 2021;10:1960. doi: 10.3390/antiox10121960.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antiox10121960</ArticleId><ArticleId IdType="pmc">PMC8750518</ArticleId><ArticleId IdType="pubmed">34943063</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrera-Van Oostdam A.S., Casta&#xf1;eda-Delgado J.E., Oropeza-Valdez J.J., Borrego J.C., Mon&#xe1;rrez-Espino J., Zheng J., Mandal R., Zhang L., Soto-Guzm&#xe1;n E., Fern&#xe1;ndez-Ruiz J.C., et al. Immunometabolic signatures predict risk of progression to sepsis in COVID-19. PLoS ONE. 2021;16:e0256784. doi: 10.1371/journal.pone.0256784.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0256784</ArticleId><ArticleId IdType="pmc">PMC8405033</ArticleId><ArticleId IdType="pubmed">34460840</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf3;pez-Hern&#xe1;ndez Y., Mon&#xe1;rrez-Espino J., Oostdam A.H., Delgado J.E.C., Zhang L., Zheng J., Valdez J.J.O., Mandal R., Gonz&#xe1;lez F.L.O., Moreno J.C.B., et al. Targeted metabolomics identifies high performing diagnostic and prognostic biomarkers for COVID-19. Sci. Rep. 2021;11:14732. doi: 10.1038/s41598-021-94171-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-94171-y</ArticleId><ArticleId IdType="pmc">PMC8290000</ArticleId><ArticleId IdType="pubmed">34282210</ArticleId></ArticleIdList></Reference><Reference><Citation>Lionetto L., Ulivieri M., Capi M., De Bernardini D., Fazio F., Petrucca A., Pomes L.M., De Luca O., Gentile G., Casolla B., et al. Increased kynurenine-to-tryptophan ratio in the serum of patients infected with SARS-CoV2: An observational cohort study. Biochim. Biophys. Acta Mol. Basis Dis. 2021;1867:166042. doi: 10.1016/j.bbadis.2020.166042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2020.166042</ArticleId><ArticleId IdType="pmc">PMC7834629</ArticleId><ArticleId IdType="pubmed">33338598</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas T., Stefanoni D., Reisz J.A., Nemkov T., Bertolone L., Francis R.O., Hudson K.E., Zimring J.C., Hansen K.C., Hod E.A., et al. COVID-19 infection alters kynurenine and fatty acid metabolism, correlating with IL-6 levels and renal status. JCI Insight. 2020;5:e140327. doi: 10.1172/jci.insight.140327.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.140327</ArticleId><ArticleId IdType="pmc">PMC7453907</ArticleId><ArticleId IdType="pubmed">32559180</ArticleId></ArticleIdList></Reference><Reference><Citation>Michaelis S., Zelzer S., Schnedl W.J., Baranyi A., Meinitzer A., Enko D. Assessment of tryptophan and kynurenine as prognostic markers in patients with SARS-CoV-2. Clin. Chim. Acta. 2021;525:29&#x2013;33. doi: 10.1016/j.cca.2021.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cca.2021.12.005</ArticleId><ArticleId IdType="pmc">PMC8662911</ArticleId><ArticleId IdType="pubmed">34902346</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaiser H., Yu K., Pandya C., Mendhe B., Isales C.M., McGee-Lawrence M.E., Johnson M., Fulzele S., Hamrick M.W. Kynurenine, a Tryptophan Metabolite That Increases with Age, Induces Muscle Atrophy and Lipid Peroxidation. Oxid. Med. Cell. Longev. 2019;2019:9894238. doi: 10.1155/2019/9894238.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2019/9894238</ArticleId><ArticleId IdType="pmc">PMC6815546</ArticleId><ArticleId IdType="pubmed">31737181</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel D., Potter M., Anaya J.M., McGee-Lawrence M.E., Hamrick M.W., Hill W.D., Isales C.M., Fulzele S. Kynurenine induces an age-related phenotype in bone marrow stromal cells. Mech. Ageing Dev. 2021;195:111464. doi: 10.1016/j.mad.2021.111464.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mad.2021.111464</ArticleId><ArticleId IdType="pubmed">33631183</ArticleId></ArticleIdList></Reference><Reference><Citation>Vyavahare S., Kumar S., Cantu N., Kolhe R., Bollag W.B., McGee-Lawrence M.E., Hill W.D., Hamrick M.W., Isales C.M., Fulzele S. Tryptophan-Kynurenine Pathway in COVID-19-Dependent Musculoskeletal Pathology: A Minireview. Mediat. Inflamm. 2021;2021:2911578. doi: 10.1155/2021/2911578.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2021/2911578</ArticleId><ArticleId IdType="pmc">PMC8492288</ArticleId><ArticleId IdType="pubmed">34621138</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin K.S., Azzolini M., Lira Ruas J. The kynurenine connection: How exercise shifts muscle tryptophan metabolism and affects energy homeostasis, the immune system, and the brain. Am. J. Physiol. Cell Physiol. 2020;318:C818&#x2013;C830. doi: 10.1152/ajpcell.00580.2019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpcell.00580.2019</ArticleId><ArticleId IdType="pubmed">32208989</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallardo-G&#xf3;mez D., Del Pozo-Cruz J., Noetel M., &#xc1;lvarez-Barbosa F., Alfonso-Rosa R.M., Del Pozo Cruz B. Optimal Dose and Type of Exercise to Improve Cognitive Function in Older Adults: A Systematic Review and Bayesian Model-Based Network Meta-Analysis of RCTs. Ageing Res. Rev. 2022;76:101591. doi: 10.1016/j.arr.2022.101591.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arr.2022.101591</ArticleId><ArticleId IdType="pubmed">35182742</ArticleId></ArticleIdList></Reference><Reference><Citation>Dotan A., David P., Arnheim D., Shoenfeld Y. The autonomic aspects of the post-COVID19 syndrome. Autoimmun. Rev. 2022;21:103071. doi: 10.1016/j.autrev.2022.103071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2022.103071</ArticleId><ArticleId IdType="pmc">PMC8848724</ArticleId><ArticleId IdType="pubmed">35182777</ArticleId></ArticleIdList></Reference><Reference><Citation>Sen A. Does serotonin deficiency lead to anosmia, ageusia, dysfunctional chemesthesis and increased severity of illness in COVID-19? Med. Hypotheses. 2021;153:110627. doi: 10.1016/j.mehy.2021.110627.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mehy.2021.110627</ArticleId><ArticleId IdType="pmc">PMC8180092</ArticleId><ArticleId IdType="pubmed">34139598</ArticleId></ArticleIdList></Reference><Reference><Citation>Iqbal Y., Al Abdulla M.A., Albrahim S., Latoo J., Kumar R., Haddad P.M. Psychiatric presentation of patients with acute SARS-CoV-2 infection: A retrospective review of 50 consecutive patients seen by a consultation-liaison psychiatry team. BJPsych Open. 2020;6:e109. doi: 10.1192/bjo.2020.85.</Citation><ArticleIdList><ArticleId IdType="doi">10.1192/bjo.2020.85</ArticleId><ArticleId IdType="pmc">PMC7484218</ArticleId><ArticleId IdType="pubmed">32907692</ArticleId></ArticleIdList></Reference><Reference><Citation>Jain A. Deregulated kynurenine metabolism&#x2014;An alternate hypothesis for COVID-19 associated anosmia. Med. Hypotheses. 2021;157:110721. doi: 10.1016/j.mehy.2021.110721.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mehy.2021.110721</ArticleId><ArticleId IdType="pmc">PMC8553410</ArticleId><ArticleId IdType="pubmed">34731682</ArticleId></ArticleIdList></Reference><Reference><Citation>Bou&#xe7;as A.P., Rheinheimer J., Lagopoulos J. Why Severe COVID-19 Patients Are at Greater Risk of Developing Depression: A Molecular Perspective. Neuroscientist. 2020;28:11&#x2013;19. doi: 10.1177/1073858420967892.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1073858420967892</ArticleId><ArticleId IdType="pubmed">33135582</ArticleId></ArticleIdList></Reference><Reference><Citation>Shader R.I. COVID-19, interferons, and depression: A commentary. Psychiatry Res. 2020;291:113198. doi: 10.1016/j.psychres.2020.113198.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.psychres.2020.113198</ArticleId><ArticleId IdType="pubmed">32535509</ArticleId></ArticleIdList></Reference><Reference><Citation>Collier M.E., Zhang S., Scrutton N.S., Giorgini F. Inflammation control and improvement of cognitive function in COVID-19 infections: Is there a role for kynurenine 3-monooxygenase inhibition? Drug Discov. Today. 2021;26:1473&#x2013;1481. doi: 10.1016/j.drudis.2021.02.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drudis.2021.02.009</ArticleId><ArticleId IdType="pmc">PMC7889466</ArticleId><ArticleId IdType="pubmed">33609782</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabacof L., Tosto-Mancuso J., Wood J., Cortes M., Kontorovich A., McCarthy D., Rizk D., Rozanski G., Breyman E., Nasr L., et al. Post-acute COVID-19 Syndrome Negatively Impacts Physical Function, Cognitive Function, Health-Related Quality of Life and Participation. Am. J. Phys. Med. Rehabil. 2022;101:48&#x2013;52. doi: 10.1097/PHM.0000000000001910.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PHM.0000000000001910</ArticleId><ArticleId IdType="pmc">PMC8667685</ArticleId><ArticleId IdType="pubmed">34686631</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes E., Wist J., Masuda R., Lodge S., Nitschke P., Kimhofer T., Loo R.L., Begum S., Boughton B., Yang R., et al. Incomplete Systemic Recovery and Metabolic Phenoreversion in Post-Acute-Phase Nonhospitalized COVID-19 Patients: Implications for Assessment of Post-Acute COVID-19 Syndrome. J. Proteome Res. 2021;20:3315&#x2013;3329. doi: 10.1021/acs.jproteome.1c00224.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jproteome.1c00224</ArticleId><ArticleId IdType="pubmed">34009992</ArticleId></ArticleIdList></Reference><Reference><Citation>Jud P., Gressenberger P., Muster V., Avian A., Meinitzer A., Strohmaier H., Sourij H., Raggam R.B., Stradner M.H., Demel U., et al. Evaluation of Endothelial Dysfunction and Inflammatory Vasculopathy after SARS-CoV-2 Infection&#x2014;A Cross-Sectional Study. Front. Cardiovasc. Med. 2021;8:750887. doi: 10.3389/fcvm.2021.750887.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2021.750887</ArticleId><ArticleId IdType="pmc">PMC8549830</ArticleId><ArticleId IdType="pubmed">34722682</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambadiari V., Mitrakou A., Kountouri A., Thymis J., Katogiannis K., Korakas E., Varlamos C., Andreadou I., Tsoumani M., Triantafyllidi H., et al. Association of COVID-19 with impaired endothelial glycocalyx, vascular function and myocardial deformation 4 months after infection. Eur. J. Heart Fail. 2021;23:1916&#x2013;1926. doi: 10.1002/ejhf.2326.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ejhf.2326</ArticleId><ArticleId IdType="pmc">PMC8426810</ArticleId><ArticleId IdType="pubmed">34415085</ArticleId></ArticleIdList></Reference><Reference><Citation>Braidy N., Grant R., Adams S., Brew B.J., Guillemin G.J. Mechanism for quinolinic acid cytotoxicity in human astrocytes and neurons. Neurotox. Res. 2009;16:77&#x2013;86. doi: 10.1007/s12640-009-9051-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12640-009-9051-z</ArticleId><ArticleId IdType="pubmed">19526301</ArticleId></ArticleIdList></Reference><Reference><Citation>Lugo-Huitr&#xf3;n R., Ugalde Mu&#xf1;iz P., Pineda B., Pedraza-Chaverr&#xed; J., R&#xed;os C., P&#xe9;rez-de la Cruz V. Quinolinic acid: An endogenous neurotoxin with multiple targets. Oxid. Med. Cell. Longev. 2013;2013:104024. doi: 10.1155/2013/104024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2013/104024</ArticleId><ArticleId IdType="pmc">PMC3780648</ArticleId><ArticleId IdType="pubmed">24089628</ArticleId></ArticleIdList></Reference><Reference><Citation>Wirthgen E., Hoeflich A., Rebl A., G&#xfc;nther J. Kynurenic Acid: The Janus-Faced Role of an Immunomodulatory Tryptophan Metabolite and Its Link to Pathological Conditions. Front. Immunol. 2018;8:1957. doi: 10.3389/fimmu.2017.01957.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.01957</ArticleId><ArticleId IdType="pmc">PMC5770815</ArticleId><ArticleId IdType="pubmed">29379504</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim C.K., Essa M.M., de Paula Martins R., Lovejoy D.B., Bilgin A.A., Waly M.I., Al-Farsi Y.M., Al-Sharbati M., Al-Shaffae M.A., Guillemin G.J. Altered kynurenine pathway metabolism in autism: Implication for immune-induced glutamatergic activity. Autism Res. 2016;9:621&#x2013;631. doi: 10.1002/aur.1565.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/aur.1565</ArticleId><ArticleId IdType="pubmed">26497015</ArticleId></ArticleIdList></Reference><Reference><Citation>Moffett J.R., Espey M.G., Gaudet S.J., Namboodiri M.A. Antibodies to quinolinic acid reveal localization in select immune cells rather than neurons or astroglia. Brain Res. 1993;623:337&#x2013;340. doi: 10.1016/0006-8993(93)91450-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0006-8993(93)91450-7</ArticleId><ArticleId IdType="pubmed">8221118</ArticleId></ArticleIdList></Reference><Reference><Citation>Heyes M.P., Achim C.L., Wiley C.A., Major E.O., Saito K., Markey S.P. Human microglia convert l-tryptophan into the neurotoxin quinolinic acid. Biochem. J. 1996;320:595&#x2013;597. doi: 10.1042/bj3200595.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/bj3200595</ArticleId><ArticleId IdType="pmc">PMC1217971</ArticleId><ArticleId IdType="pubmed">8973572</ArticleId></ArticleIdList></Reference><Reference><Citation>Guillemin G.J. Quinolinic acid, the inescapable neurotoxin. FEBS J. 2012;279:1356&#x2013;1365. doi: 10.1111/j.1742-4658.2012.08485.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1742-4658.2012.08485.x</ArticleId><ArticleId IdType="pubmed">22248144</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang Y., Xie S., He Y., Xu M., Qiao X., Zhu Y., Wu W. Kynurenine Pathway Metabolites as Biomarkers in Alzheimer&#x2019;s Disease. Dis. Markers. 2022;2022:9484217. doi: 10.1155/2022/9484217.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2022/9484217</ArticleId><ArticleId IdType="pmc">PMC8791723</ArticleId><ArticleId IdType="pubmed">35096208</ArticleId></ArticleIdList></Reference><Reference><Citation>Myint A.M., Kim Y.K. Network beyond IDO in psychiatric disorders: Revisiting neurodegeneration hypothesis. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2014;48:304&#x2013;313. doi: 10.1016/j.pnpbp.2013.08.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pnpbp.2013.08.008</ArticleId><ArticleId IdType="pubmed">24184687</ArticleId></ArticleIdList></Reference><Reference><Citation>Venkatesan D., Iyer M., Narayanasamy A., Siva K., Vellingiri B. Kynurenine pathway in Parkinson&#x2019;s disease&#x2014;An update. Eneurologicalsci. 2020;21:100270. doi: 10.1016/j.ensci.2020.100270.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ensci.2020.100270</ArticleId><ArticleId IdType="pmc">PMC7585940</ArticleId><ArticleId IdType="pubmed">33134567</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunt C., Macedo E., Cordeiro T., Suchting R., de Dios C., Cuellar Leal V.A., Soares J.C., Dantzer R., Teixeira A.L., Selvaraj S. Effect of immune activation on the kynurenine pathway and depression symptoms&#x2014;A systematic review and meta-analysis. Neurosci. Biobehav. Rev. 2020;118:514&#x2013;523. doi: 10.1016/j.neubiorev.2020.08.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neubiorev.2020.08.010</ArticleId><ArticleId IdType="pmc">PMC8087452</ArticleId><ArticleId IdType="pubmed">32853625</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhai L., Ladomersky E., Bell A., Dussold C., Cardoza K., Qian J., Lauing K.L., Wainwright D.A. Quantification of IDO1 enzyme activity in normal and malignant tissues. Methods Enzymol. 2019;629:235&#x2013;256. doi: 10.1016/bs.mie.2019.07.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/bs.mie.2019.07.006</ArticleId><ArticleId IdType="pmc">PMC7347075</ArticleId><ArticleId IdType="pubmed">31727243</ArticleId></ArticleIdList></Reference><Reference><Citation>Silvano A., Seravallii V., Strambi N., Cecchi M., Tartarotti E., Parenti A., Di Tommaso M. Tryptophan metabolism and immune regulation in the human placenta. J. Reprod. Immunol. 2021;147:103361. doi: 10.1016/j.jri.2021.103361.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jri.2021.103361</ArticleId><ArticleId IdType="pubmed">34365162</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamazaki F., Kuroiwa T., Takikawa O., Kido R. Human indolylamine 2,3-dioxygenase. Its tissue distribution and characterization of the placental enzyme. Biochem. J. 1985;230:635&#x2013;638. doi: 10.1042/bj2300635.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/bj2300635</ArticleId><ArticleId IdType="pmc">PMC1152665</ArticleId><ArticleId IdType="pubmed">3877502</ArticleId></ArticleIdList></Reference><Reference><Citation>Munn D.H., Sharma M.D., Hou D., Baban B., Lee J.R., Antonia S.J., Messina J.L., Chandler P., Koni P.A., Mellor A.L. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J. Clin. Investig. 2004;114:280&#x2013;290. doi: 10.1172/JCI21583.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI21583</ArticleId><ArticleId IdType="pmc">PMC449750</ArticleId><ArticleId IdType="pubmed">15254595</ArticleId></ArticleIdList></Reference><Reference><Citation>Th&#xe9;ate I., van Baren N., Pilotte L., Moulin P., Larrieu P., Renauld J.C., Herv&#xe9; C., Gutierrez-Roelens I., Marbaix E., Sempoux C., et al. Extensive profiling of the expression of the indoleamine 2,3-dioxygenase 1 protein in normal and tumoral human tissues. Cancer Immunol. Res. 2015;3:161&#x2013;172. doi: 10.1158/2326-6066.CIR-14-0137.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2326-6066.CIR-14-0137</ArticleId><ArticleId IdType="pubmed">25271151</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#xe4;ubener W., Schmidt S.K., Heseler K., Spekker K.H., MacKenzie C.R. Antimicrobial and immunoregulatory effector mechanisms in human endothelial cells. Thromb. Haemost. 2009;102:1110&#x2013;1116. doi: 10.1160/TH09-04-0250.</Citation><ArticleIdList><ArticleId IdType="doi">10.1160/TH09-04-0250</ArticleId><ArticleId IdType="pubmed">19967141</ArticleId></ArticleIdList></Reference><Reference><Citation>Trabanelli S., O&#x10d;adl&#xed;kov&#xe1; D., Ciciarello M., Salvestrini V., Lecciso M., Jandus C., Metz R., Evangelisti C., Laury-Kleintop L., Romero P., et al. The SOCS3-independent expression of IDO2 supports the homeostatic generation of T regulatory cells by human dendritic cells. J. Immunol. 2014;192:1231&#x2013;1240. doi: 10.4049/jimmunol.1300720.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1300720</ArticleId><ArticleId IdType="pmc">PMC3905741</ArticleId><ArticleId IdType="pubmed">24391212</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo L., Schurink B., Roos E., Nossent E.J., Duitman J.W., Vlaar A.P.J., van der Valk P., Vaz F.M., Yeh S.-R., Geeraerts Z., et al. Indoleamine 2,3-dioxygenase (IDO)-1 and IDO-2 activity and severe course of COVID-19. J. Pathol. 2021;256:256&#x2013;261. doi: 10.1002/path.5842.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/path.5842</ArticleId><ArticleId IdType="pmc">PMC8897979</ArticleId><ArticleId IdType="pubmed">34859884</ArticleId></ArticleIdList></Reference><Reference><Citation>Blaschitz A., Gauster M., Fuchs D., Lang I., Maschke P., Ulrich D., Karpf E., Takikawa O., Schimek M.G., Dohr G., et al. Vascular endothelial expression of indoleamine 2,3-dioxygenase 1 forms a positive gradient towards the feto-maternal interface. PLoS ONE. 2011;6:e21774. doi: 10.1371/journal.pone.0021774.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0021774</ArticleId><ArticleId IdType="pmc">PMC3130744</ArticleId><ArticleId IdType="pubmed">21755000</ArticleId></ArticleIdList></Reference><Reference><Citation>Kudo Y., Koh I., Sugimoto J. Localization of Indoleamine 2,3-Dioxygenase-1 and Indoleamine 2,3-Dioxygenase-2 at the Human Maternal-Fetal Interface. Int. J. Tryptophan Res. 2020;13:1178646920984163. doi: 10.1177/1178646920984163.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1178646920984163</ArticleId><ArticleId IdType="pmc">PMC7780199</ArticleId><ArticleId IdType="pubmed">33447047</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X., Wei H. Role of Decidual Natural Killer Cells in Human Pregnancy and Related Pregnancy Complications. Front. Immunol. 2021;12:728291. doi: 10.3389/fimmu.2021.728291.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.728291</ArticleId><ArticleId IdType="pmc">PMC8426434</ArticleId><ArticleId IdType="pubmed">34512661</ArticleId></ArticleIdList></Reference><Reference><Citation>Zardoya-Laguardia P., Blaschitz A., Hirschmugl B., Lang I., Herzog S.A., Nikitina L., Gauster M., H&#xe4;usler M., Cervar-Zivkovic M., Karpf E., et al. Endothelial indoleamine 2,3-dioxygenase-1 regulates the placental vascular tone and is deficient in intrauterine growth restriction and pre-eclampsia. Sci. Rep. 2018;8:5488. doi: 10.1038/s41598-018-23896-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-23896-0</ArticleId><ArticleId IdType="pmc">PMC5883010</ArticleId><ArticleId IdType="pubmed">29615752</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishizawa H., Hasegawa K., Suzuki M., Kamoshida S., Kato T., Saito K., Tsutsumi Y., Kurahashi H., Udagawa Y. The etiological role of allogeneic fetal rejection in pre-eclampsia. Am. J. Reprod. Immunol. 2007;58:11&#x2013;20. doi: 10.1111/j.1600-0897.2007.00484.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0897.2007.00484.x</ArticleId><ArticleId IdType="pubmed">17565543</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishizawa H., Suzuki M., Pryor-Koishi K., Sekiya T., Tada S., Kurahashi H., Udagawa Y. Impact of indoleamine 2,3-dioxygenase on the antioxidant system in the placentas of severely pre-eclamptic patients. Syst. Biol. Reprod. Med. 2011;57:174&#x2013;178. doi: 10.3109/19396368.2011.587590.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/19396368.2011.587590</ArticleId><ArticleId IdType="pubmed">21718232</ArticleId></ArticleIdList></Reference><Reference><Citation>Santillan M.K., Pelham C.J., Ketsawatsomkron P., Santillan D.A., Davis D.R., Devor E.J., Gibson-Corley K.N., Scroggins S.M., Grobe J.L., Yang B., et al. Pregnant mice lacking indoleamine 2,3-dioxygenase exhibit preeclampsia phenotypes. Physiol. Rep. 2015;3:e12257. doi: 10.14814/phy2.12257.</Citation><ArticleIdList><ArticleId IdType="doi">10.14814/phy2.12257</ArticleId><ArticleId IdType="pmc">PMC4387753</ArticleId><ArticleId IdType="pubmed">25602015</ArticleId></ArticleIdList></Reference><Reference><Citation>Broekhuizen M., Danser A.H.J., Reiss I.K.M., Merkus D. The Function of the Kynurenine Pathway in the Placenta: A Novel Pharmacotherapeutic Target? Int. J. Environ. Res. Public Health. 2021;18:11545. doi: 10.3390/ijerph182111545.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph182111545</ArticleId><ArticleId IdType="pmc">PMC8582682</ArticleId><ArticleId IdType="pubmed">34770059</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Liu H., McKenzie G., Witting P.K., Stasch J.P., Hahn M., Changsirivathanathamrong D., Wu B.J., Ball H.J., Thomas S.R., et al. Kynurenine is an endothelium-derived relaxing factor produced during inflammation. Nat. Med. 2010;16:279&#x2013;285. doi: 10.1038/nm.2092.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.2092</ArticleId><ArticleId IdType="pmc">PMC3556275</ArticleId><ArticleId IdType="pubmed">20190767</ArticleId></ArticleIdList></Reference><Reference><Citation>Worton S.A., Greenwood S.L., Wareing M., Heazell A.E., Myers J. The kynurenine pathway; A new target for treating maternal features of preeclampsia? Placenta. 2019;84:44&#x2013;49. doi: 10.1016/j.placenta.2019.04.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.placenta.2019.04.007</ArticleId><ArticleId IdType="pubmed">31076094</ArticleId></ArticleIdList></Reference><Reference><Citation>Worton S.A., Pritchard H.A.T., Greenwood S.L., Alakrawi M., Heazell A.E.P., Wareing M., Greenstein A., Myers J.E. Kynurenine Relaxes Arteries of Normotensive Women and Those with Preeclampsia. Circ. Res. 2021;128:1679&#x2013;1693. doi: 10.1161/CIRCRESAHA.120.317612.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.120.317612</ArticleId><ArticleId IdType="pmc">PMC8154175</ArticleId><ArticleId IdType="pubmed">33656370</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanley C.P., Maghzal G.J., Ayer A., Talib J., Giltrap A.M., Shengule S., Wolhuter K., Wang Y., Chadha P., Suarna C., et al. Singlet molecular oxygen regulates vascular tone and blood pressure in inflammation. Nature. 2019;566:548&#x2013;552. doi: 10.1038/s41586-019-0947-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-019-0947-3</ArticleId><ArticleId IdType="pubmed">30760924</ArticleId></ArticleIdList></Reference><Reference><Citation>Kass D.A. Fresh evidence overturns the identification of a factor involved in blood-vessel dilation. Nature. 2019;566:462&#x2013;464. doi: 10.1038/d41586-019-00508-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-019-00508-z</ArticleId><ArticleId IdType="pubmed">30809049</ArticleId></ArticleIdList></Reference><Reference><Citation>Watts S.W., Shaw S., Burnett R., Dorrance A.M. Indoleamine 2,3-diooxygenase in periaortic fat: Mechanisms of inhibition of contraction. Am. J. Physiol. Heart Circ. Physiol. 2011;301:H1236&#x2013;H1247. doi: 10.1152/ajpheart.00384.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpheart.00384.2011</ArticleId><ArticleId IdType="pmc">PMC3197349</ArticleId><ArticleId IdType="pubmed">21841011</ArticleId></ArticleIdList></Reference><Reference><Citation>Struijk P.C., Mathews V.J., Loupas T., Stewart P.A., Clark E.B., Steegers E.A., Wladimiroff J.W. Blood pressure estimation in the human fetal descending aorta. Ultrasound Obstet. Gynecol. 2008;32:673&#x2013;681. doi: 10.1002/uog.6137.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/uog.6137</ArticleId><ArticleId IdType="pubmed">18816497</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao Y., Christou H., Liu L., Visner G., Mitsialis S.A., Kourembanas S., Liu H. Endothelial indoleamine 2,3-dioxygenase protects against development of pulmonary hypertension. Am. J. Respir. Crit. Care Med. 2013;188:482&#x2013;491. doi: 10.1164/rccm.201304-0700OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.201304-0700OC</ArticleId><ArticleId IdType="pmc">PMC3778740</ArticleId><ArticleId IdType="pubmed">23822766</ArticleId></ArticleIdList></Reference><Reference><Citation>Jasiewicz M., Moniuszko M., Pawlak D., Knapp M., Rusak M., Kazimierczyk R., Musial W.J., Dabrowska M., Kaminski K.A. Activity of the kynurenine pathway and its interplay with immunity in patients with pulmonary arterial hypertension. Heart. 2016;102:230&#x2013;237. doi: 10.1136/heartjnl-2015-308581.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/heartjnl-2015-308581</ArticleId><ArticleId IdType="pubmed">26769378</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagy B.M., Nagaraj C., Meinitzer A., Sharma N., Papp R., Foris V., Ghanim B., Kwapiszewska G., Kovacs G., Klepetko W., et al. Importance of kynurenine in pulmonary hypertension. Am. J. Physiol. Lung Cell. Mol. Physiol. 2017;313:L741&#x2013;L751. doi: 10.1152/ajplung.00517.2016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajplung.00517.2016</ArticleId><ArticleId IdType="pubmed">28705908</ArticleId></ArticleIdList></Reference><Reference><Citation>Pellegrin K., Neurauter G., Wirleitner B., Fleming A.W., Peterson V.M., Fuchs D. Enhanced enzymatic degradation of tryptophan by indoleamine 2,3-dioxygenase contributes to the tryptophan-deficient state seen after major trauma. Shock. 2005;23:209&#x2013;215.</Citation><ArticleIdList><ArticleId IdType="pubmed">15718917</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung I.D., Lee M.G., Chang J.H., Lee J.S., Jeong Y.I., Lee C.M., Park W.S., Han J., Seo S.K., Lee S.Y., et al. Blockade of indoleamine 2,3-dioxygenase protects mice against lipopolysaccharide-induced endotoxin shock. J. Immunol. 2009;182:3146&#x2013;3154. doi: 10.4049/jimmunol.0803104.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.0803104</ArticleId><ArticleId IdType="pubmed">19234212</ArticleId></ArticleIdList></Reference><Reference><Citation>Changsirivathanathamrong D., Wang Y., Rajbhandari D., Maghzal G.J., Mak W.M., Woolfe C., Duflou J., Gebski V., dos Remedios C.G., Celermajer D.S., et al. Tryptophan metabolism to kynurenine is a potential novel contributor to hypotension in human sepsis. Crit. Care Med. 2011;39:2678&#x2013;2683. doi: 10.1097/CCM.0b013e31822827f2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0b013e31822827f2</ArticleId><ArticleId IdType="pubmed">21765346</ArticleId></ArticleIdList></Reference><Reference><Citation>Darcy C.J., Davis J.S., Woodberry T., McNeil Y.R., Stephens D.P., Yeo T.W., Anstey N.M. An observational cohort study of the kynurenine to tryptophan ratio in sepsis: Association with impaired immune and microvascular function. PLoS ONE. 2011;6:e21185. doi: 10.1371/journal.pone.0021185.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0021185</ArticleId><ArticleId IdType="pmc">PMC3120841</ArticleId><ArticleId IdType="pubmed">21731667</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedberg J.S., Van Meurs M., Kielstein J.T., Martens-Lobenhoffer J., Bode-B&#xf6;ger S.M., Zijlstra J.G., Kovesdy C.P., K&#xfc;mpers P. Indoleamine-2,3-dioxygenase activity in experimental human endotoxemia. Exp. Transl. Stroke Med. 2012;4:24. doi: 10.1186/2040-7378-4-24.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/2040-7378-4-24</ArticleId><ArticleId IdType="pmc">PMC3560239</ArticleId><ArticleId IdType="pubmed">23216784</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu H., Liu L., Visner G.A. Nonviral gene delivery with indoleamine 2,3-dioxygenase targeting pulmonary endothelium protects against ischemia-reperfusion injury. Am. J. Transplant. 2007;7:2291&#x2013;2300. doi: 10.1111/j.1600-6143.2007.01942.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-6143.2007.01942.x</ArticleId><ArticleId IdType="pubmed">17711549</ArticleId></ArticleIdList></Reference><Reference><Citation>Cole J.E., Astola N., Cribbs A.P., Goddard M.E., Park I., Green P., Davies A.H., Williams R.O., Feldmann M., Monaco C. Indoleamine 2,3-dioxygenase-1 is protective in atherosclerosis and its metabolites provide new opportunities for drug development. Proc. Natl. Acad. Sci. USA. 2015;112:13033&#x2013;13038. doi: 10.1073/pnas.1517820112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1517820112</ArticleId><ArticleId IdType="pmc">PMC4620898</ArticleId><ArticleId IdType="pubmed">26438837</ArticleId></ArticleIdList></Reference><Reference><Citation>Forteza M.J., Polyzos K.A., Baumgartner R., Suur B.E., Mussbacher M., Johansson D.K., Hermansson A., Hansson G.K., Ketelhuth D.F.J. Activation of the Regulatory T-Cell/Indoleamine 2,3-Dioxygenase Axis Reduces Vascular Inflammation and Atherosclerosis in Hyperlipidemic Mice. Front. Immunol. 2018;9:950. doi: 10.3389/fimmu.2018.00950.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.00950</ArticleId><ArticleId IdType="pmc">PMC5949314</ArticleId><ArticleId IdType="pubmed">29867939</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolowczuk I., Hennart B., Leloire A., Bessede A., Soichot M., Taront S., Caiazzo R., Raverdy V., Pigeyre M., ABOS Consortium et al. Tryptophan metabolism activation by indoleamine 2,3-dioxygenase in adipose tissue of obese women: An attempt to maintain immune homeostasis and vascular tone. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2012;303:R135&#x2013;R143. doi: 10.1152/ajpregu.00373.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpregu.00373.2011</ArticleId><ArticleId IdType="pubmed">22592557</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S.M., Park H.Y., Suh Y.S., Yoon E.H., Kim J., Jang W.H., Lee W.S., Park S.G., Choi I.W., Choi I., et al. Inhibition of acute lethal pulmonary inflammation by the IDO-AhR pathway. Proc. Natl. Acad. Sci. USA. 2017;114:E5881&#x2013;E5890. doi: 10.1073/pnas.1615280114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1615280114</ArticleId><ArticleId IdType="pmc">PMC5530642</ArticleId><ArticleId IdType="pubmed">28673995</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans P.C., Rainger G.E., Mason J.C., Guzik T.J., Osto E., Stamataki Z., Neil D., Hoefer I.E., Fragiadaki M., Waltenberger J., et al. Endothelial dysfunction in COVID-19: A position paper of the ESC Working Group for Atherosclerosis and Vascular Biology and the ESC Council of Basic Cardiovascular Science. Cardiovasc. Res. 2020;116:2177&#x2013;2184. doi: 10.1093/cvr/cvaa230.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cvr/cvaa230</ArticleId><ArticleId IdType="pmc">PMC7454368</ArticleId><ArticleId IdType="pubmed">32750108</ArticleId></ArticleIdList></Reference><Reference><Citation>Potus F., Mai V., Lebret M., Malenfant S., Breton-Gagnon E., Lajoie A.C., Boucherat O., Bonnet S., Provencher S. Novel insights on the pulmonary vascular consequences of COVID-19. Am. J. Physiol. Lung. Cell. Mol. Physiol. 2020;319:L277&#x2013;L288. doi: 10.1152/ajplung.00195.2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajplung.00195.2020</ArticleId><ArticleId IdType="pmc">PMC7414237</ArticleId><ArticleId IdType="pubmed">32551862</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonaventura A., Vecchi&#xe9; A., Dagna L., Martinod K., Dixon D.L., Van Tassell B.W., Dentali F., Montecucco F., Massberg S., Levi M., et al. Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19. Nat. Rev. Immunol. 2021;21:319&#x2013;329. doi: 10.1038/s41577-021-00536-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-021-00536-9</ArticleId><ArticleId IdType="pmc">PMC8023349</ArticleId><ArticleId IdType="pubmed">33824483</ArticleId></ArticleIdList></Reference><Reference><Citation>Mejia-Renteria H., Travieso A., Sagir A., Mart&#xed;nez-G&#xf3;mez E., Carrascosa-Granada A., Toya T., N&#xfa;&#xf1;ez-Gil I.J., Estrada V., Lerman A., Escaned J. In-vivo evidence of systemic endothelial vascular dysfunction in COVID-19. Int. J. Cardiol. 2021;345:153&#x2013;155. doi: 10.1016/j.ijcard.2021.10.140.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2021.10.140</ArticleId><ArticleId IdType="pmc">PMC8542397</ArticleId><ArticleId IdType="pubmed">34706286</ArticleId></ArticleIdList></Reference><Reference><Citation>N&#xe4;gele M.P., Haubner B., Tanner F.C., Ruschitzka F., Flammer A.J. Endothelial dysfunction in COVID-19: Current findings and therapeutic implications. Atherosclerosis. 2020;314:58&#x2013;62. doi: 10.1016/j.atherosclerosis.2020.10.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.atherosclerosis.2020.10.014</ArticleId><ArticleId IdType="pmc">PMC7554490</ArticleId><ArticleId IdType="pubmed">33161318</ArticleId></ArticleIdList></Reference><Reference><Citation>Mangalmurti N.S., Reilly J.P., Cines D.B., Meyer N.J., Hunter C.A., Vaughan A.E. COVID-19-associated Acute Respiratory Distress Syndrome Clarified: A Vascular Endotype? Am. J. Respir. Crit. Care Med. 2020;202:750&#x2013;753. doi: 10.1164/rccm.202006-2598LE.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.202006-2598LE</ArticleId><ArticleId IdType="pmc">PMC7462395</ArticleId><ArticleId IdType="pubmed">32631071</ArticleId></ArticleIdList></Reference><Reference><Citation>Maruhashi T., Higashi Y. Pathophysiological Association of Endothelial Dysfunction with Fatal Outcome in COVID-19. Int. J. Mol. Sci. 2021;22:5131. doi: 10.3390/ijms22105131.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22105131</ArticleId><ArticleId IdType="pmc">PMC8150852</ArticleId><ArticleId IdType="pubmed">34066226</ArticleId></ArticleIdList></Reference><Reference><Citation>Cimino G., Vizzardi E., Calvi E., Pancaldi E., Pascariello G., Bernardi N., Cersosimo A., Amore L., Inciardi R.M., Raddino R., et al. Endothelial dysfunction in COVID-19 patients assessed with Endo-PAT2000. Monaldi Arch. Chest Dis. 2022 doi: 10.4081/monaldi.2022.2213.</Citation><ArticleIdList><ArticleId IdType="doi">10.4081/monaldi.2022.2213</ArticleId><ArticleId IdType="pubmed">35179012</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen A.T., Wang C.Y., Zhu W.L., Chen W. Coagulation Disorders and Thrombosis in COVID-19 Patients and a Possible Mechanism Involving Endothelial Cells: A Review. Aging Dis. 2022;13:144&#x2013;156. doi: 10.14336/AD.2021.0704.</Citation><ArticleIdList><ArticleId IdType="doi">10.14336/AD.2021.0704</ArticleId><ArticleId IdType="pmc">PMC8782553</ArticleId><ArticleId IdType="pubmed">35111367</ArticleId></ArticleIdList></Reference><Reference><Citation>Teuwen L.A., Geldhof V., Pasut A., Carmeliet P. COVID-19: The vasculature unleashed. Nat. Rev. Immunol. 2020;20:389&#x2013;391. doi: 10.1038/s41577-020-0343-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-020-0343-0</ArticleId><ArticleId IdType="pmc">PMC7240244</ArticleId><ArticleId IdType="pubmed">32439870</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin Y., Ji W., Yang H., Chen S., Zhang W., Duan G. Endothelial activation and dysfunction in COVID-19: From basic mechanisms to potential therapeutic approaches. Signal Transduct. Target. Ther. 2020;5:293. doi: 10.1038/s41392-020-00454-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-020-00454-7</ArticleId><ArticleId IdType="pmc">PMC7758411</ArticleId><ArticleId IdType="pubmed">33361764</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernard I., Limonta D., Mahal L.K., Hobman T.C. Endothelium Infection and Dysregulation by SARS-CoV-2: Evidence and Caveats in COVID-19. Viruses. 2020;13:29. doi: 10.3390/v13010029.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13010029</ArticleId><ArticleId IdType="pmc">PMC7823949</ArticleId><ArticleId IdType="pubmed">33375371</ArticleId></ArticleIdList></Reference><Reference><Citation>Ackermann M., Verleden S.E., Kuehnel M., Haverich A., Welte T., Laenger F., Vanstapel A., Werlein C., Stark H., Tzankov A., et al. Pulmonary Vascular Endothelialitis, Thrombosis and Angiogenesis in COVID-19. N. Engl. J. Med. 2020;383:120&#x2013;128. doi: 10.1056/NEJMoa2015432.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2015432</ArticleId><ArticleId IdType="pmc">PMC7412750</ArticleId><ArticleId IdType="pubmed">32437596</ArticleId></ArticleIdList></Reference><Reference><Citation>Varga Z., Flammer A.J., Steiger P., Haberecker M., Andermatt R., Zinkernagel A.S., Mehra M.R., Schuepbach R.A., Ruschitzka F., Moch H. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395:1417&#x2013;1418. doi: 10.1016/S0140-6736(20)30937-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30937-5</ArticleId><ArticleId IdType="pmc">PMC7172722</ArticleId><ArticleId IdType="pubmed">32325026</ArticleId></ArticleIdList></Reference><Reference><Citation>McCracken I.R., Saginc G., He L., Huseynov A., Daniels A., Fletcher S., Peghaire C., Kalna V., Andaloussi-M&#xe4;e M., Muhl L., et al. Lack of Evidence of Angiotensin-Converting Enzyme 2 Expression and Replicative Infection by SARS-CoV-2 in Human Endothelial Cells. Circulation. 2021;143:865&#x2013;868. doi: 10.1161/CIRCULATIONAHA.120.052824.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.120.052824</ArticleId><ArticleId IdType="pmc">PMC7899720</ArticleId><ArticleId IdType="pubmed">33405941</ArticleId></ArticleIdList></Reference><Reference><Citation>Rauch A., Dupont A., Goutay J., Caplan M., Staessens S., Moussa M., Jeanpierre E., Corseaux D., Lefevre G., Lassalle F., et al. Endotheliopathy Is Induced by Plasma from Critically Ill Patients and Associated with Organ Failure in Severe COVID-19. Circulation. 2020;142:1881&#x2013;1884. doi: 10.1161/CIRCULATIONAHA.120.050907.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.120.050907</ArticleId><ArticleId IdType="pmc">PMC7643783</ArticleId><ArticleId IdType="pubmed">32970476</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki Y.J., Nikolaienko S.I., Dibrova V.A., Dibrova Y.V., Vasylyk V.M., Novikov M.Y., Shults N.V., Gychka S.G. SARS-CoV-2 spike protein-mediated cell signaling in lung vascular cells. Vascul. Pharmacol. 2021;137:106823. doi: 10.1016/j.vph.2020.106823.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vph.2020.106823</ArticleId><ArticleId IdType="pmc">PMC7680014</ArticleId><ArticleId IdType="pubmed">33232769</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan S., Shafiei M.S., Longoria C., Schoggins J.W., Savani R.C., Zaki H. SARS-CoV-2 spike protein induces inflammation via TLR2-dependent activation of the NF-&#x3ba;B pathway. Elife. 2021;10:e68563. doi: 10.7554/eLife.68563.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.68563</ArticleId><ArticleId IdType="pmc">PMC8709575</ArticleId><ArticleId IdType="pubmed">34866574</ArticleId></ArticleIdList></Reference><Reference><Citation>Raghavan S., Kenchappa D.B., Leo M.D. SARS-CoV-2 Spike Protein Induces Degradation of Junctional Proteins that Maintain Endothelial Barrier Integrity. Front. Cardiovasc. Med. 2021;8:687783. doi: 10.3389/fcvm.2021.687783.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2021.687783</ArticleId><ArticleId IdType="pmc">PMC8225996</ArticleId><ArticleId IdType="pubmed">34179146</ArticleId></ArticleIdList></Reference><Reference><Citation>Olajide O.A., Iwuanyanwu V.U., Lepiarz-Raba I., Al-Hindawi A.A. Induction of Exaggerated Cytokine Production in Human Peripheral Blood Mononuclear Cells by a Recombinant SARS-CoV-2 Spike Glycoprotein S1 and Its Inhibition by Dexamethasone. Inflammation. 2021;44:1865&#x2013;1877. doi: 10.1007/s10753-021-01464-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10753-021-01464-5</ArticleId><ArticleId IdType="pmc">PMC8050229</ArticleId><ArticleId IdType="pubmed">33860869</ArticleId></ArticleIdList></Reference><Reference><Citation>Robles J.P., Zamora M., Adan-Castro E., Siqueiros-Marquez L., Martinez de la Escalera G., Clapp C. The spike protein of SARS-CoV-2 induces endothelial inflammation through integrin &#x3b1;5&#x3b2;1 and NF-&#x3ba;B signaling. J. Biol. Chem. 2022;298:101695. doi: 10.1016/j.jbc.2022.101695.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbc.2022.101695</ArticleId><ArticleId IdType="pmc">PMC8820157</ArticleId><ArticleId IdType="pubmed">35143839</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei Y., Zhang J., Schiavon C.R., He M., Chen L., Shen H., Zhang Y., Yin Q., Cho Y., Andrade L., et al. SARS-CoV-2 Spike Protein Impairs Endothelial Function via Downregulation of ACE 2. Circ. Res. 2021;128:1323&#x2013;1326. doi: 10.1161/CIRCRESAHA.121.318902.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.121.318902</ArticleId><ArticleId IdType="pmc">PMC8091897</ArticleId><ArticleId IdType="pubmed">33784827</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim E.S., Jeon M.T., Kim K.S., Lee S., Kim S., Kim D.G. Spike Proteins of SARS-CoV-2 Induce Pathological Changes in Molecular Delivery and Metabolic Function in the Brain Endothelial Cells. Viruses. 2021;13:2021. doi: 10.3390/v13102021.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13102021</ArticleId><ArticleId IdType="pmc">PMC8538996</ArticleId><ArticleId IdType="pubmed">34696455</ArticleId></ArticleIdList></Reference><Reference><Citation>Julliard W., Fechner J.H., Mezrich J.D. The aryl hydrocarbon receptor meets immunology: Friend or foe? A little of both. Front. Immunol. 2014;5:458. doi: 10.3389/fimmu.2014.00458.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2014.00458</ArticleId><ArticleId IdType="pmc">PMC4183121</ArticleId><ArticleId IdType="pubmed">25324842</ArticleId></ArticleIdList></Reference><Reference><Citation>Poulain-Godefroy O., Bout&#xe9; M., Carrard J., Alvarez-Simon D., Tsicopoulos A., de Nadai P. The Aryl Hydrocarbon Receptor in Asthma: Friend or Foe? Int. J. Mol. Sci. 2020;21:8797. doi: 10.3390/ijms21228797.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21228797</ArticleId><ArticleId IdType="pmc">PMC7699852</ArticleId><ArticleId IdType="pubmed">33233810</ArticleId></ArticleIdList></Reference><Reference><Citation>Takei H., Yasuoka H., Yoshimoto K., Takeuchi T. Aryl hydrocarbon receptor signals attenuate lung fibrosis in the bleomycin-induced mouse model for pulmonary fibrosis through increase of regulatory T cells. Arthritis Res. Ther. 2020;22:20. doi: 10.1186/s13075-020-2112-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-020-2112-7</ArticleId><ArticleId IdType="pmc">PMC7006193</ArticleId><ArticleId IdType="pubmed">32033616</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu S.M., Tsai J.J., Pan H.C., Arbiser J.L., Elia L., Sheu M.L. Aggravation of pulmonary fibrosis after knocking down the aryl hydrocarbon receptor in the insulin-like growth factor 1 receptor pathway. Br. J. Pharmacol. 2022 doi: 10.1111/bph.15806.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.15806</ArticleId><ArticleId IdType="pubmed">35083738</ArticleId></ArticleIdList></Reference><Reference><Citation>Engin A.B., Engin E.D., Engin A. The effect of environmental pollution on immune evasion checkpoints of SARS-CoV-2. Environ. Toxicol. Pharmacol. 2021;81:103520. doi: 10.1016/j.etap.2020.103520.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.etap.2020.103520</ArticleId><ArticleId IdType="pmc">PMC7580701</ArticleId><ArticleId IdType="pubmed">33132153</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson G., Carbone A., Mazzoccoli G. Tryptophan Metabolites and Aryl Hydrocarbon Receptor in Severe Acute Respiratory Syndrome, Coronavirus-2 (SARS-CoV-2) Pathophysiology. Int. J. Mol. Sci. 2021;22:1597. doi: 10.3390/ijms22041597.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22041597</ArticleId><ArticleId IdType="pmc">PMC7915649</ArticleId><ArticleId IdType="pubmed">33562472</ArticleId></ArticleIdList></Reference><Reference><Citation>Ball H.J., Yuasa H.J., Austin C.J., Weiser S., Hunt N.H. Indoleamine 2,3-dioxygenase-2; a new enzyme in the kynurenine pathway. Int. J. Biochem. Cell Biol. 2009;41:467&#x2013;471. doi: 10.1016/j.biocel.2008.01.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biocel.2008.01.005</ArticleId><ArticleId IdType="pubmed">18282734</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen A.M., Ball H.J., Mitchell A.J., Miu J., Takikawa O., Hunt N.H. Increased expression of indoleamine 2,3-dioxygenase in murine malaria infection is predominantly localised to the vascular endothelium. Int. J. Parasitol. 2004;34:1309&#x2013;1319. doi: 10.1016/j.ijpara.2004.07.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpara.2004.07.008</ArticleId><ArticleId IdType="pubmed">15542091</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox J.M., Crabtree J.M., Sage L.K., Tompkins S.M., Tripp R.A. Interferon Lambda Upregulates IDO1 Expression in Respiratory Epithelial Cells after Influenza Virus Infection. J. Interferon Cytokine Res. 2015;35:554&#x2013;562. doi: 10.1089/jir.2014.0052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/jir.2014.0052</ArticleId><ArticleId IdType="pmc">PMC4507134</ArticleId><ArticleId IdType="pubmed">25756191</ArticleId></ArticleIdList></Reference><Reference><Citation>Metz R., Duhadaway J.B., Kamasani U., Laury-Kleintop L., Muller A.J., Prendergast G.C. Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. Cancer Res. 2007;67:7082&#x2013;7087. doi: 10.1158/0008-5472.CAN-07-1872.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-07-1872</ArticleId><ArticleId IdType="pubmed">17671174</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto Y., Yamasuge W., Imai S., Kunisawa K., Hoshi M., Fujigaki H., Mouri A., Nabeshima T., Saito K. Lipopolysaccharide shock reveals the immune function of indoleamine 2,3-dioxygenase 2 through the regulation of IL-6/stat3 signalling. Sci. Rep. 2018;8:15917. doi: 10.1038/s41598-018-34166-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-34166-4</ArticleId><ArticleId IdType="pmc">PMC6206095</ArticleId><ArticleId IdType="pubmed">30374077</ArticleId></ArticleIdList></Reference><Reference><Citation>Belladonna M.L., Orabona C. Potential Benefits of Tryptophan Metabolism to the Efficacy of Tocilizumab in COVID-19. Front. Pharmacol. 2020;11:959. doi: 10.3389/fphar.2020.00959.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2020.00959</ArticleId><ArticleId IdType="pmc">PMC7319082</ArticleId><ArticleId IdType="pubmed">32636755</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu X., Han M., Li T., Sun W., Wang D., Fu B., Zhou Y., Zheng X., Yang Y., Li X., et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc. Natl. Acad. Sci. USA. 2020;117:10970&#x2013;10975. doi: 10.1073/pnas.2005615117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2005615117</ArticleId><ArticleId IdType="pmc">PMC7245089</ArticleId><ArticleId IdType="pubmed">32350134</ArticleId></ArticleIdList></Reference><Reference><Citation>Bronte V., Ugel S., Tinazzi E., Vella A., De Sanctis F., Can&#xe8; S., Batani V., Trovato R., Fiore A., Petrova V., et al. Baricitinib restrains the immune dysregulation in patients with severe COVID-19. J. Clin. Investig. 2020;130:6409&#x2013;6416. doi: 10.1172/JCI141772.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI141772</ArticleId><ArticleId IdType="pmc">PMC8016181</ArticleId><ArticleId IdType="pubmed">32809969</ArticleId></ArticleIdList></Reference><Reference><Citation>Grunewald M.E., Shaban M.G., Mackin S.R., Fehr A.R., Perlman S. Murine Coronavirus Infection Activates the Aryl Hydrocarbon Receptor in an Indoleamine 2,3-Dioxygenase-Independent Manner, Contributing to Cytokine Modulation and Proviral TCDD-Inducible-PARP Expression. J. Virol. 2020;94:e01743&#x2013;19. doi: 10.1128/JVI.01743-19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01743-19</ArticleId><ArticleId IdType="pmc">PMC7000979</ArticleId><ArticleId IdType="pubmed">31694960</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukunaga M., Yamamoto Y., Kawasoe M., Arioka Y., Murakami Y., Hoshi M., Saito K. Studies on tissue and cellular distribution of indoleamine 2,3-dioxygenase 2: The absence of IDO1 upregulates IDO2 expression in the epididymis. J. Histochem. Cytochem. 2012;60:854&#x2013;860. doi: 10.1369/0022155412458926.</Citation><ArticleIdList><ArticleId IdType="doi">10.1369/0022155412458926</ArticleId><ArticleId IdType="pmc">PMC3524572</ArticleId><ArticleId IdType="pubmed">22895526</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakagawa K., Kobayashi F., Kamei Y., Tawa M., Ohkita M. Acute Kynurenine Exposure of Rat Thoracic Aorta Induces Vascular Dysfunction via Superoxide Anion Production. Biol. Pharm. Bull. 2022;45:522&#x2013;527. doi: 10.1248/bpb.b21-01079.</Citation><ArticleIdList><ArticleId IdType="doi">10.1248/bpb.b21-01079</ArticleId><ArticleId IdType="pubmed">35370278</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadi H.A., Carr C.S., Al Suwaidi J. Endothelial dysfunction: Cardiovascular risk factors, therapy, and outcome. Vasc. Health Risk Manag. 2005;1:183&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1993955</ArticleId><ArticleId IdType="pubmed">17319104</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q., Zhang M., Ding Y., Wang Q., Zhang W., Song P., Zou M.H. Activation of NAD(P)H oxidase by tryptophan-derived 3-hydroxykynurenine accelerates endothelial apoptosis and dysfunction in vivo. Circ. Res. 2014;114:480&#x2013;492. doi: 10.1161/CIRCRESAHA.114.302113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.114.302113</ArticleId><ArticleId IdType="pmc">PMC4104160</ArticleId><ArticleId IdType="pubmed">24281189</ArticleId></ArticleIdList></Reference><Reference><Citation>Karmouty-Quintana H., Thandavarayan R.A., Keller S.P., Sahay S., Pandit L.M., Akkanti B. Emerging Mechanisms of Pulmonary Vasoconstriction in SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (ARDS) and Potential Therapeutic Targets. Int. J. Mol. Sci. 2020;21:8081. doi: 10.3390/ijms21218081.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21218081</ArticleId><ArticleId IdType="pmc">PMC7662604</ArticleId><ArticleId IdType="pubmed">33138181</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikolaidis A., Kramer R., Ostojic S. Nitric Oxide: The Missing Factor in COVID-19 Severity? Med. Sci. 2021;10:3. doi: 10.3390/medsci10010003.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/medsci10010003</ArticleId><ArticleId IdType="pmc">PMC8788438</ArticleId><ArticleId IdType="pubmed">35076566</ArticleId></ArticleIdList></Reference><Reference><Citation>Montiel V., Lobysheva I., G&#xe9;rard L., Vermeersch M., Perez-Morga D., Castelein T., Mesland J.B., Hantson P., Collienne C., Gruson D., et al. Oxidative stress-induced endothelial dysfunction and decreased vascular nitric oxide in COVID-19 patients. EBioMedicine. 2022;77:103893. doi: 10.1016/j.ebiom.2022.103893.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2022.103893</ArticleId><ArticleId IdType="pmc">PMC8865837</ArticleId><ArticleId IdType="pubmed">35219085</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamenshchikov N.O., Berra L., Carroll R.W. Therapeutic Effects of Inhaled Nitric Oxide Therapy in COVID-19 Patients. Biomedicines. 2022;10:369. doi: 10.3390/biomedicines10020369.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines10020369</ArticleId><ArticleId IdType="pmc">PMC8962307</ArticleId><ArticleId IdType="pubmed">35203578</ArticleId></ArticleIdList></Reference><Reference><Citation>Samelson-Jones B.J., Yeh S.R. Interactions between nitric oxide and indoleamine 2,3-dioxygenase. Biochemistry. 2006;45:8527&#x2013;8538. doi: 10.1021/bi060143j.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi060143j</ArticleId><ArticleId IdType="pubmed">16834326</ArticleId></ArticleIdList></Reference><Reference><Citation>Melillo G., Cox G.W., Biragyn A., Sheffler L.A., Varesio L. Regulation of nitric-oxide synthase mRNA expression by interferon-gamma and picolinic acid. J. Biol. Chem. 1994;269:8128&#x2013;8133. doi: 10.1016/S0021-9258(17)37169-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0021-9258(17)37169-7</ArticleId><ArticleId IdType="pubmed">7510678</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim Y.J., Foo T.C., Yeung A.W.S., Tu X., Ma Y., Hawkins C.L., Witting P.K., Jameson G.N.L., Terentis A.C., Thomas S.R. Human Indoleamine 2,3-Dioxygenase 1 Is an Efficient Mammalian Nitrite Reductase. Biochemistry. 2019;58:974&#x2013;986. doi: 10.1021/acs.biochem.8b01231.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.biochem.8b01231</ArticleId><ArticleId IdType="pubmed">30585477</ArticleId></ArticleIdList></Reference><Reference><Citation>Prendergast G.C., Metz R., Muller A.J., Merlo L.M., Mandik-Nayak L. IDO2 in Immunomodulation and Autoimmune Disease. Front. Immunol. 2014;5:585. doi: 10.3389/fimmu.2014.00585.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2014.00585</ArticleId><ArticleId IdType="pmc">PMC4238401</ArticleId><ArticleId IdType="pubmed">25477879</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan Y., Zhang G.X., Gran B., Fallarino F., Yu S., Li H., Cullimore M.L., Rostami A., Xu H. IDO upregulates regulatory T cells via tryptophan catabolite and suppresses encephalitogenic T cell responses in experimental autoimmune encephalomyelitis. J. Immunol. 2010;185:5953&#x2013;5961. doi: 10.4049/jimmunol.1001628.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1001628</ArticleId><ArticleId IdType="pmc">PMC2998795</ArticleId><ArticleId IdType="pubmed">20944000</ArticleId></ArticleIdList></Reference><Reference><Citation>Wetzel L.A., Hurtado M., MacDowell Kaswan Z.A., McCusker R.H., Steelman A.J. Deletion of indoleamine 2,3 dioxygenase (Ido)1 but not Ido2 exacerbates disease symptoms of MOG35&#x2013;55-induced experimental autoimmune encephalomyelitis. Brain Behav. Immun. Health. 2020;7:100116. doi: 10.1016/j.bbih.2020.100116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbih.2020.100116</ArticleId><ArticleId IdType="pmc">PMC8474387</ArticleId><ArticleId IdType="pubmed">34589873</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan R.N., Yang C.L., Du T., Liu A., Wang A.R., Sun W.J., Li X., Li J.X., Yan C.Z., Liu Q.J. Smek1 deficiency exacerbates experimental autoimmune encephalomyelitis by activating proinflammatory microglia and suppressing the IDO1-AhR pathway. J. Neuroinflammation. 2021;18:145. doi: 10.1186/s12974-021-02193-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-021-02193-0</ArticleId><ArticleId IdType="pmc">PMC8237434</ArticleId><ArticleId IdType="pubmed">34183017</ArticleId></ArticleIdList></Reference><Reference><Citation>Correale J. Immunosuppressive Amino-Acid Catabolizing Enzymes in Multiple Sclerosis. Front. Immunol. 2021;11:600428. doi: 10.3389/fimmu.2020.600428.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.600428</ArticleId><ArticleId IdType="pmc">PMC7855700</ArticleId><ArticleId IdType="pubmed">33552055</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y., Han T., Chen J., Hou C., Hua L., He S., Guo Y., Zhang S., Wang Y., Yuan J., et al. Clinical and Autoimmune Characteristics of Severe and Critical Cases of COVID-19. Clin. Transl. Sci. 2020;13:1077&#x2013;1086. doi: 10.1111/cts.12805.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cts.12805</ArticleId><ArticleId IdType="pmc">PMC7264560</ArticleId><ArticleId IdType="pubmed">32315487</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y., Sawalha A.H., Lu Q. COVID-19 and autoimmune diseases. Curr. Opin. Rheumatol. 2021;33:155&#x2013;162. doi: 10.1097/BOR.0000000000000776.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BOR.0000000000000776</ArticleId><ArticleId IdType="pmc">PMC7880581</ArticleId><ArticleId IdType="pubmed">33332890</ArticleId></ArticleIdList></Reference><Reference><Citation>Lv H., Chen T., Pan Y., Wang H., Chen L., Lu Y. Pulmonary vascular enlargement on thoracic CT for diagnosis and differential diagnosis of COVID-19: A systematic review and meta-analysis. Ann. Transl. Med. 2020;8:878. doi: 10.21037/atm-20-4955.</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/atm-20-4955</ArticleId><ArticleId IdType="pmc">PMC7396779</ArticleId><ArticleId IdType="pubmed">32793722</ArticleId></ArticleIdList></Reference><Reference><Citation>Piciucchi S., Ravaglia C., Vizzuso A., Bertocco M., Poletti V. Reversibility of venous dilatation and parenchymal changes density in Sars-Cov-2 pneumonia: Toward the definition of a peculiar pattern. Pulmonology. 2021;27:353&#x2013;357. doi: 10.1016/j.pulmoe.2020.10.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pulmoe.2020.10.010</ArticleId><ArticleId IdType="pmc">PMC7667388</ArticleId><ArticleId IdType="pubmed">33272912</ArticleId></ArticleIdList></Reference><Reference><Citation>Gattinoni L., Chiumello D., Caironi P., Busana M., Romitti F., Brazzi L., Camporota L. COVID-19 pneumonia: Different respiratory treatments for different phenotypes? Intensive Care Med. 2020;46:1099&#x2013;1102. doi: 10.1007/s00134-020-06033-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-020-06033-2</ArticleId><ArticleId IdType="pmc">PMC7154064</ArticleId><ArticleId IdType="pubmed">32291463</ArticleId></ArticleIdList></Reference><Reference><Citation>Gattinoni L., Coppola S., Cressoni M., Busana M., Rossi S., Chiumello D. COVID-19 Does Not Lead to a &#x201c;Typical&#x201d; Acute Respiratory Distress Syndrome. Am. J. Respir. Crit. Care Med. 2020;201:1299&#x2013;1300. doi: 10.1164/rccm.202003-0817LE.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.202003-0817LE</ArticleId><ArticleId IdType="pmc">PMC7233352</ArticleId><ArticleId IdType="pubmed">32228035</ArticleId></ArticleIdList></Reference><Reference><Citation>Simonato M., Dall&#x2019;Acqua S., Zilli C., Sut S., Tenconi R., Gallo N., Sfriso P., Sartori L., Cavallin F., Fiocco U., et al. Tryptophan Metabolites, Cytokines, and Fatty Acid Binding Protein 2 in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Biomedicines. 2021;9:1724. doi: 10.3390/biomedicines9111724.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines9111724</ArticleId><ArticleId IdType="pmc">PMC8615774</ArticleId><ArticleId IdType="pubmed">34829952</ArticleId></ArticleIdList></Reference><Reference><Citation>Komaroff A.L., Lipkin W.I. Insights from myalgic encephalomyelitis/chronic fatigue syndrome may help unravel the pathogenesis of postacute COVID-19 syndrome. Trends Mol. Med. 2021;27:895&#x2013;906. doi: 10.1016/j.molmed.2021.06.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2021.06.002</ArticleId><ArticleId IdType="pmc">PMC8180841</ArticleId><ArticleId IdType="pubmed">34175230</ArticleId></ArticleIdList></Reference><Reference><Citation>Phetsouphanh C., Darley D.R., Wilson D.B., Howe A., Munier C.M.L., Patel S.K., Juno J.A., Burrell L.M., Kent S.J., Dore G.J., et al. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat. Immunol. 2022;23:210&#x2013;216. doi: 10.1038/s41590-021-01113-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01113-x</ArticleId><ArticleId IdType="pubmed">35027728</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen T., Wang T. Metabolic Reprogramming in COVID-19. Int. J. Mol. Sci. 2021;22:11475. doi: 10.3390/ijms222111475.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms222111475</ArticleId><ArticleId IdType="pmc">PMC8584248</ArticleId><ArticleId IdType="pubmed">34768906</ArticleId></ArticleIdList></Reference><Reference><Citation>Adebayo A., Varzideh F., Wilson S., Gambardella J., Eacobacci M., Jankauskas S.S., Donkor K., Kansakar U., Trimarco V., Mone P., et al. l-Arginine and COVID-19: An Update. Nutrients. 2021;13:3951. doi: 10.3390/nu13113951.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu13113951</ArticleId><ArticleId IdType="pmc">PMC8619186</ArticleId><ArticleId IdType="pubmed">34836206</ArticleId></ArticleIdList></Reference><Reference><Citation>Rees C.A., Rostad C.A., Mantus G., Anderson E.J., Chahroudi A., Jaggi P., Wrammert J., Ochoa J.B., Ochoa A., Basu R.K., et al. Altered amino acid profile in patients with SARS-CoV-2 infection. Proc. Natl. Acad. Sci. USA. 2021;118:e2101708118. doi: 10.1073/pnas.2101708118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2101708118</ArticleId><ArticleId IdType="pmc">PMC8237604</ArticleId><ArticleId IdType="pubmed">34088793</ArticleId></ArticleIdList></Reference><Reference><Citation>Young S.N., Leyton M. The role of serotonin in human mood and social interaction. Insight from altered tryptophan levels. Pharmacol. Biochem. Behav. 2002;71:857&#x2013;865. doi: 10.1016/S0091-3057(01)00670-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0091-3057(01)00670-0</ArticleId><ArticleId IdType="pubmed">11888576</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernstrom J.D. Effects and side effects associated with the non-nutritional use of tryptophan by humans. J. Nutr. 2012;142:2236S&#x2013;2244S. doi: 10.3945/jn.111.157065.</Citation><ArticleIdList><ArticleId IdType="doi">10.3945/jn.111.157065</ArticleId><ArticleId IdType="pubmed">23077193</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohajeri M.H., Wittwer J., Vargas K., Hogan E., Holmes A., Rogers P.J., Goralczyk R., Gibson E.L. Chronic treatment with a tryptophan-rich protein hydrolysate improves emotional processing, mental energy levels and reaction time in middle-aged women. Br. J. Nutr. 2015;113:350&#x2013;365. doi: 10.1017/S0007114514003754.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0007114514003754</ArticleId><ArticleId IdType="pubmed">25572038</ArticleId></ArticleIdList></Reference><Reference><Citation>Steenbergen L., Jongkees B.J., Sellaro R., Colzato L.S. Tryptophan supplementation modulates social behavior: A review. Neurosci. Biobehav. Rev. 2016;64:346&#x2013;358. doi: 10.1016/j.neubiorev.2016.02.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neubiorev.2016.02.022</ArticleId><ArticleId IdType="pubmed">26987640</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibson E.L., Vargas K., Hogan E., Holmes A., Rogers P.J., Wittwer J., Kloek J., Goralczyk R., Mohajeri M.H. Effects of acute treatment with a tryptophan-rich protein hydrolysate on plasma amino acids, mood and emotional functioning in older women. Psychopharmacology. 2014;231:4595&#x2013;4610. doi: 10.1007/s00213-014-3609-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00213-014-3609-z</ArticleId><ArticleId IdType="pmc">PMC4231284</ArticleId><ArticleId IdType="pubmed">24858376</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibson E.L. Tryptophan supplementation and serotonin function: Genetic variations in behavioural effects. Proc. Nutr. Soc. 2018;77:174&#x2013;188. doi: 10.1017/S0029665117004451.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0029665117004451</ArticleId><ArticleId IdType="pubmed">29368666</ArticleId></ArticleIdList></Reference><Reference><Citation>Chojnacki C., Pop&#x142;awski T., Chojnacki J., Fila M., Konrad P., Blasiak J. Tryptophan Intake and Metabolism in Older Adults with Mood Disorders. Nutrients. 2020;12:3183. doi: 10.3390/nu12103183.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu12103183</ArticleId><ArticleId IdType="pmc">PMC7603218</ArticleId><ArticleId IdType="pubmed">33081001</ArticleId></ArticleIdList></Reference><Reference><Citation>Kikuchi A.M., Tanabe A., Iwahori Y. A systematic review of the effect of L-tryptophan supplementation on mood and emotional functioning. J. Diet Suppl. 2021;18:316&#x2013;333. doi: 10.1080/19390211.2020.1746725.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/19390211.2020.1746725</ArticleId><ArticleId IdType="pubmed">32272859</ArticleId></ArticleIdList></Reference><Reference><Citation>Zamoscik V., Schmidt S.N.L., Bravo R., Ugartemendia L., Plieger T., Rodr&#xed;guez A.B., Reuter M., Kirsch P. Tryptophan-enriched diet or 5-hydroxytryptophan supplementation given in a randomized controlled trial impacts social cognition on a neural and behavioral level. Sci. Rep. 2021;11:21637. doi: 10.1038/s41598-021-01164-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-01164-y</ArticleId><ArticleId IdType="pmc">PMC8568973</ArticleId><ArticleId IdType="pubmed">34737364</ArticleId></ArticleIdList></Reference><Reference><Citation>Hole&#x10d;ek M. Side effects of amino acid supplements. Physiol. Res. 2022;71:29. doi: 10.33549/physiolres.934790.</Citation><ArticleIdList><ArticleId IdType="doi">10.33549/physiolres.934790</ArticleId><ArticleId IdType="pmc">PMC8997670</ArticleId><ArticleId IdType="pubmed">35043647</ArticleId></ArticleIdList></Reference><Reference><Citation>Valente-Silva P., Cervenka I., Ferreira D.M.S., Correia J.C., Edman S., Horwath O., Heng B., Chow S., Jacobs K.R., Guillemin G.J., et al. Effects of Tryptophan Supplementation and Exercise on the Fate of Kynurenine Metabolites in Mice and Humans. Metabolites. 2021;11:508. doi: 10.3390/metabo11080508.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/metabo11080508</ArticleId><ArticleId IdType="pmc">PMC8400416</ArticleId><ArticleId IdType="pubmed">34436450</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun C., Sun Y., Wu P., Ding W., Wang S., Li J., Liang L., Chai C., Fu Y., Li Z., et al. Longitudinal multi-omics transition associated with fatality in critically ill COVID-19 patients. Intensive Care Med. Exp. 2021;9:13. doi: 10.1186/s40635-021-00373-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40635-021-00373-z</ArticleId><ArticleId IdType="pmc">PMC7957447</ArticleId><ArticleId IdType="pubmed">33721144</ArticleId></ArticleIdList></Reference><Reference><Citation>Shukla M., Chinchalongporn V., Govitrapong P., Reiter R.J. The role of melatonin in targeting cell signaling pathways in neurodegeneration. Ann. N.Y. Acad. Sci. 2019;1443:75&#x2013;96. doi: 10.1111/nyas.14005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nyas.14005</ArticleId><ArticleId IdType="pubmed">30756405</ArticleId></ArticleIdList></Reference><Reference><Citation>Jauhari A., Baranov S.V., Suofu Y., Kim J., Singh T., Yablonska S., Li F., Wang X., Oberly P., Minnigh M.B., et al. Melatonin inhibits cytosolic mitochondrial DNA-induced neuroinflammatory signaling in accelerated aging and neurodegeneration. J. Clin. Investig. 2020;130:3124&#x2013;3136. doi: 10.1172/JCI135026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI135026</ArticleId><ArticleId IdType="pmc">PMC7260019</ArticleId><ArticleId IdType="pubmed">32182222</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo F., Sandhu A.F., Rungratanawanich W., Williams G.E., Akbar M., Zhou S., Song B.J., Wang X. Melatonin and Autophagy in Aging-Related Neurodegenerative Diseases. Int. J. Mol. Sci. 2020;21:7174. doi: 10.3390/ijms21197174.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21197174</ArticleId><ArticleId IdType="pmc">PMC7584015</ArticleId><ArticleId IdType="pubmed">32998479</ArticleId></ArticleIdList></Reference><Reference><Citation>Maher A.M., Saleh S.R., Elguindy N.M., Hashem H.M., Yacout G.A. Exogenous melatonin restrains neuroinflammation in high fat diet induced diabetic rats through attenuating indoleamine 2,3-dioxygenase 1 expression. Life Sci. 2020;247:117427. doi: 10.1016/j.lfs.2020.117427.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2020.117427</ArticleId><ArticleId IdType="pubmed">32067945</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang Y., Groom K., Chamley L., Chen Q. Melatonin, a Potential Therapeutic Agent for Preeclampsia, Reduces the Extrusion of Toxic Extracellular Vesicles from Preeclamptic Placentae. Cells. 2021;10:1904. doi: 10.3390/cells10081904.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10081904</ArticleId><ArticleId IdType="pmc">PMC8393242</ArticleId><ArticleId IdType="pubmed">34440672</ArticleId></ArticleIdList></Reference><Reference><Citation>Bologna C., Madonna P., Pone E. Efficacy of Prolonged-Release Melatonin 2 mg (PRM 2 mg) Prescribed for Insomnia in Hospitalized Patients for COVID-19: A Retrospective Observational Study. J. Clin. Med. 2021;10:5857. doi: 10.3390/jcm10245857.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10245857</ArticleId><ArticleId IdType="pmc">PMC8705392</ArticleId><ArticleId IdType="pubmed">34945156</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarrott B., Head R., Pringle K.G., Lumbers E.R., Martin J.H. &#x201c;LONG COVID&#x201d;-A hypothesis for understanding the biological basis and pharmacological treatment strategy. Pharmacol. Res. Perspect. 2022;10:e00911. doi: 10.1002/prp2.911.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/prp2.911</ArticleId><ArticleId IdType="pmc">PMC8929332</ArticleId><ArticleId IdType="pubmed">35029046</ArticleId></ArticleIdList></Reference><Reference><Citation>Sen A. Deficient synthesis of melatonin in COVID-19 can impair the resistance of coronavirus patients to mucormycosis. Med. Hypotheses. 2021;158:110722. doi: 10.1016/j.mehy.2021.110722.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mehy.2021.110722</ArticleId><ArticleId IdType="pmc">PMC8553412</ArticleId><ArticleId IdType="pubmed">34753008</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown G.M., Pandi-Perumal S.R., Pupko H., Kennedy J.L., Cardinali D.P. Melatonin as an Add-On Treatment of COVID-19 Infection: Current Status. Diseases. 2021;9:64. doi: 10.3390/diseases9030064.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/diseases9030064</ArticleId><ArticleId IdType="pmc">PMC8482145</ArticleId><ArticleId IdType="pubmed">34562971</ArticleId></ArticleIdList></Reference><Reference><Citation>Shchetinin E., Baturin V., Arushanyan E., Bolatchiev A., Bobryshev D. Potential and Possible Therapeutic Effects of Melatonin on SARS-CoV-2 Infection. Antioxidants. 2022;11:140. doi: 10.3390/antiox11010140.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antiox11010140</ArticleId><ArticleId IdType="pmc">PMC8772978</ArticleId><ArticleId IdType="pubmed">35052644</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan D.X., Reiter R.J. Mechanisms and clinical evidence to support melatonin&#x2019;s use in severe COVID-19 patients to lower mortality. Life Sci. 2022;294:120368. doi: 10.1016/j.lfs.2022.120368.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2022.120368</ArticleId><ArticleId IdType="pmc">PMC8800937</ArticleId><ArticleId IdType="pubmed">35108568</ArticleId></ArticleIdList></Reference><Reference><Citation>Lan S.H., Lee H.Z., Chao C.M., Chang S.P., Lu L.C., Lai C.C. Efficacy of melatonin in the treatment of patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials. J. Med. Virol. 2022;94:2102&#x2013;2107. doi: 10.1002/jmv.27595.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27595</ArticleId><ArticleId IdType="pmc">PMC9015545</ArticleId><ArticleId IdType="pubmed">35032042</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasan Z.T., Mal Allah Al Atrakji M.Q.Y., Mehuaiden D.A.K. The Effect of Melatonin on Thrombosis, Sepsis and Mortality Rate in COVID-19 Patients. Int. J. Infect. Dis. 2022;114:79&#x2013;84. doi: 10.1016/j.ijid.2021.10.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2021.10.012</ArticleId><ArticleId IdType="pmc">PMC8506572</ArticleId><ArticleId IdType="pubmed">34653660</ArticleId></ArticleIdList></Reference><Reference><Citation>Essa M.M., Hamdan H., Chidambaram S.B., Al-Balushi B., Guillemin G.J., Ojcius D.M., Qoronfleh M.W. Possible role of tryptophan and melatonin in COVID-19. Int. J. Tryptophan Res. 2020;13:1178646920951832. doi: 10.1177/1178646920951832.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1178646920951832</ArticleId><ArticleId IdType="pmc">PMC7443751</ArticleId><ArticleId IdType="pubmed">32913393</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleszczy&#x144;ski K., Slominski A.T., Steinbrink K., Reiter R.J. Clinical Trials for Use of Melatonin to Fight against COVID-19 Are Urgently Needed. Nutrients. 2020;12:2561. doi: 10.3390/nu12092561.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu12092561</ArticleId><ArticleId IdType="pmc">PMC7551551</ArticleId><ArticleId IdType="pubmed">32847033</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodr&#xed;guez-Rubio M., Figueira J.C., Acu&#xf1;a-Castroviejo D., Borobia A.M., Escames G., de la Oliva P. A phase II, single-center, double-blind, randomized placebo-controlled trial to explore the efficacy and safety of intravenous melatonin in patients with COVID-19 admitted to the intensive care unit (MelCOVID study): A structured summary of a study protocol for a randomized controlled trial. Trials. 2020;21:699. doi: 10.1186/s13063-020-04632-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13063-020-04632-4</ArticleId><ArticleId IdType="pmc">PMC7403786</ArticleId><ArticleId IdType="pubmed">32758298</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziaei A., Davoodian P., Dadvand H., Safa O., Hassanipour S., Omidi M., Masjedi M., Mahmoudikia F., Rafiee B., Fathalipour M. Evaluation of the efficacy and safety of Melatonin in moderately ill patients with COVID-19: A structured summary of a study protocol for a randomized controlled trial. Trials. 2020;21:882. doi: 10.1186/s13063-020-04737-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13063-020-04737-w</ArticleId><ArticleId IdType="pmc">PMC7586647</ArticleId><ArticleId IdType="pubmed">33106171</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwashita H., Matsumoto Y., Maruyama Y., Watanabe K., Chiba A., Hattori A. The melatonin metabolite N1-acetyl-5-methoxykynuramine facilitates long-term object memory in young and aging mice. J. Pineal Res. 2021;70:e12703. doi: 10.1111/jpi.12703.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jpi.12703</ArticleId><ArticleId IdType="pmc">PMC7816253</ArticleId><ArticleId IdType="pubmed">33125735</ArticleId></ArticleIdList></Reference><Reference><Citation>Song Z., Bao L., Deng W., Liu J., Ren E., Lv Q., Liu M., Qi F., Chen T., Deng R., et al. Integrated histopathological, lipidomic, and metabolomic profiles reveal mink is a useful animal model to mimic the pathogenicity of severe COVID-19 patients. Signal Transduct. Target. Ther. 2022;7:29. doi: 10.1038/s41392-022-00891-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-022-00891-6</ArticleId><ArticleId IdType="pmc">PMC8795751</ArticleId><ArticleId IdType="pubmed">35091528</ArticleId></ArticleIdList></Reference><Reference><Citation>Schefold J.C., Zeden J.P., Pschowski R., Hammoud B., Fotopoulou C., Hasper D., Fusch G., Von Haehling S., Volk H.D., Meisel C., et al. Treatment with granulocyte-macrophage colony-stimulating factor is associated with reduced indoleamine 2,3-dioxygenase activity and kynurenine pathway catabolites in patients with severe sepsis and septic shock. Scand. J. Infect. Dis. 2010;42:164&#x2013;171. doi: 10.3109/00365540903405768.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/00365540903405768</ArticleId><ArticleId IdType="pubmed">19958238</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh R., Salunke D.B. Diverse chemical space of indoleamine-2,3-dioxygenase 1 (Ido1) inhibitors. Eur. J. Med. Chem. 2021;211:113071. doi: 10.1016/j.ejmech.2020.113071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmech.2020.113071</ArticleId><ArticleId IdType="pubmed">33341650</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhai L., Spranger S., Binder D.C., Gritsina G., Lauing K.L., Giles F.J., Wainwright D.A. Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy. Clin. Cancer Res. 2015;21:5427&#x2013;5433. doi: 10.1158/1078-0432.CCR-15-0420.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-15-0420</ArticleId><ArticleId IdType="pmc">PMC4681601</ArticleId><ArticleId IdType="pubmed">26519060</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim M., Tomek P. Tryptophan: A Rheostat of Cancer Immune Escape Mediated by Immunosuppressive Enzymes IDO1 and TDO. Front. Immunol. 2021;12:636081. doi: 10.3389/fimmu.2021.636081.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.636081</ArticleId><ArticleId IdType="pmc">PMC7940516</ArticleId><ArticleId IdType="pubmed">33708223</ArticleId></ArticleIdList></Reference><Reference><Citation>Breda C., Sathyasaikumar K.V., Sograte Idrissi S., Notarangelo F.M., Estranero J.G., Moore G.G., Green E.W., Kyriacou C.P., Schwarcz R., Giorgini F. Tryptophan-2,3-dioxygenase (TDO) inhibition ameliorates neurodegeneration by modulation of kynurenine pathway metabolites. Proc. Natl. Acad. Sci. USA. 2016;113:5435&#x2013;5440. doi: 10.1073/pnas.1604453113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1604453113</ArticleId><ArticleId IdType="pmc">PMC4868470</ArticleId><ArticleId IdType="pubmed">27114543</ArticleId></ArticleIdList></Reference><Reference><Citation>Brochez L., Chevolet I., Kruse V. The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy. Eur. J. Cancer. 2017;76:167&#x2013;182. doi: 10.1016/j.ejca.2017.01.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejca.2017.01.011</ArticleId><ArticleId IdType="pubmed">28324751</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheong J.E., Ekkati A., Sun L. A patent review of IDO1 inhibitors for cancer. Expert Opin. Ther. Pat. 2018;28:317&#x2013;330. doi: 10.1080/13543776.2018.1441290.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13543776.2018.1441290</ArticleId><ArticleId IdType="pubmed">29473428</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheong J.E., Sun L. Targeting the IDO1/TDO2-KYN-AhR Pathway for Cancer Immunotherapy&#x2014;Challenges and Opportunities. Trends Pharmacol. Sci. 2018;39:307&#x2013;325. doi: 10.1016/j.tips.2017.11.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tips.2017.11.007</ArticleId><ArticleId IdType="pubmed">29254698</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakmiwewa S.M., Fatokun A.A., Tran A., Payne R.J., Hunt N.H., Ball H.J. Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2. Bioorg. Med. Chem. Lett. 2012;22:7641&#x2013;7646. doi: 10.1016/j.bmcl.2012.10.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmcl.2012.10.010</ArticleId><ArticleId IdType="pubmed">23122865</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng X., Shen P., Wang Y., Li Z., Bian J. Synthesis and in vivo antitumor evaluation of an orally active potent phosphonamidate derivative targeting IDO1/IDO2/TDO. Biochem. Pharmacol. 2019;168:214&#x2013;223. doi: 10.1016/j.bcp.2019.07.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bcp.2019.07.011</ArticleId><ArticleId IdType="pubmed">31306643</ArticleId></ArticleIdList></Reference><Reference><Citation>Capochiani de Iudicibus R., Tomek P., Palmer B.D., Tijono S.M., Flanagan J.U., Ching L.M. Parallel discovery of selective and dual inhibitors of tryptophan dioxygenases IDO1 and TDO2 with a newly-modified enzymatic assay. Bioorg. Med. Chem. 2021;39:116160. doi: 10.1016/j.bmc.2021.116160.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmc.2021.116160</ArticleId><ArticleId IdType="pubmed">33901770</ArticleId></ArticleIdList></Reference><Reference><Citation>He X., He G., Chu Z., Wu H., Wang J., Ge Y., Shen H., Zhang S., Shan J., Peng K., et al. Discovery of the First Potent IDO1/IDO2 Dual Inhibitors: A Promising Strategy for Cancer Immunotherapy. J. Med. Chem. 2021;64:17950&#x2013;17968. doi: 10.1021/acs.jmedchem.1c01305.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.1c01305</ArticleId><ArticleId IdType="pubmed">34854662</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen C., Edgley A.J., Kelly D.J., Kompa A.R. Aryl Hydrocarbon Receptor Inhibition Restores Indoxyl Sulfate-Mediated Endothelial Dysfunction in Rat Aortic Rings. Toxins. 2022;14:100. doi: 10.3390/toxins14020100.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/toxins14020100</ArticleId><ArticleId IdType="pmc">PMC8878015</ArticleId><ArticleId IdType="pubmed">35202128</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>